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Summary 
 
Metabotropic  glutamate  receptor  subtype  7  (mGluR7)  belongs  to  the  family  of  G-protein 
coupled  receptors.  mGluR7  is  widely  distributed  in  the  brain  and  primarily  localized  at 
presynaptic terminals, where it is thought to regulate neurotransmitter release and synaptic 
plasticity. Studies have shown that the intracellular C-terminal tail of mGluR7 binds a variety 
of proteins in addition to trimeric G-proteins. These newly identified protein interactions are 
believed to play a key role in the synaptic targeting and G-protein dependent signaling of 
mGluR7.  Protein  interacting  with  C  kinase  1  (PICK1),  a  PDZ-domain  protein,  is  a  strong 
interaction  partner  of  mGluR7a.  In  order  to  investigate  the  role  of  PICK1  in  the  synaptic 
trafficking  and  signaling  of  mGluR7a,  a  knock-in  mouse  line  in  which  the  interaction  of 
mGluR7a  and  PICK1  is  disrupted  was  generated.  Analysis  of  the  mutant  mice  by 
immunocytochemistry  and  immunoelectron  microscopy  showed  that  the  synaptic  targeting 
and clustering of mGluR7a was not altered, indicating that PICK1 is not required for mGluR7a 
receptor  membrane  trafficking  and  synaptic  localization.  However,  when  the  spontaneous 
synaptic activity of cerebellar granule cell cultures prepared from both wild-type and knock-in 
mice was monitored, and L-AP4 (400µm) was found to decrease the frequency, but not the 
amplitude, of spontaneous excitatory currents in wild-type neurons, while no effect of L-AP4 
on  spontaneous  synaptic  activity  was  observed  in  knock-in  neurons.  This  indicates  that 
PICK1  binding  to  the  C-terminal  region  of  mGluR7a  plays  an  essential  role  in  mGluR7a 
mediated  G-protein  signaling.  We  examined  the  threshold  sensitivity  for  the  convulsant 
pentetrazole (PTZ) in knock-in mice. It was found that mGluR7a knock-in mice had a greater 
sensitivity to PTZ than wild-type mice. Moreover, the surface parietal cortex EEG recordings 
of  the  mutant  mice  revealed  spontaneous  synchronous  oscillation,  or  "spike-and-wave 
discharges" (SWD), which displayed similar characteristics to absence-like seizures. It was 
also  observed  that  the  knock-in  mice  responded  to  pharmacology  as  human  absence 
epilepsy. These data suggests that the knock-in mice displayed the phenotype of absence-
like epilepsy. Furthermore, the behavioral analysis of the mGluR7a knock-in mice showed no 
deficits in motor coordination, pain sensation, anxiety as well as spatial learning and memory, 
thus the interaction of mGluR7a and PICK1 appears not to contribute to these physiological 
processes. Taken together, our data provides evidence for an important role of PICK1 in G-
protein  dependent  signaling  of  mGluR7a,  whereas  PICK1  is  not  required  for  synaptic 
targeting and clustering of mGluR7a. Our results also provide an animal model of absence-
like epilepsy generated by disruption of a single mGluR7a-PDZ interaction, thus creating a 
novel therapeutic target against this neurological disease.  
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1. Introduction 
 
1.1. Synapses and synaptic transmission 
 
The  information  processing  capacity  of  the  central  nervous  system  (CNS)  is 
achieved  by  synapses,  which  are  very  important  structures  for  communication 
between  nerve  cells  and  their  target  cells  (neurons,  muscle  or  gland  cells).  Two 
distinct types of synapses are identified: electrical synapses and chemical synapses 
(Gundelfinger and tom Dieck, 2000). Electrical synapses are formed by gap junctions 
and conduct electrical activity directly from one cell to another, they are rarely found 
in the vertebrate nervous system. The vast majority of the synapses in the vertebrate 
brains  are  chemical  synapses,  which  need  particular  molecules  to  transmit  the 
signals. The chemical synapse is a specialized junctional complex consisting of: a 
presynaptic  ending  that  contains  neurotransmitters,  mitochondria  and  other  cell 
organelles;  a  synaptic  cleft  or  space  between  the  presynaptic  and  postsynaptic 
endings  and  a  postsynaptic  apparatus  that  contains  receptor  sites  for 
neurotransmitters (Figure 1A). Based on electron microscopic investigations by Gray 
(Gray,  1959)  and  Hamlyn  (Hamlyn,  1962),  two  types  of  chemical  synapse  are 
distinguished in the central  nervous system.  Type I junction is a type of synapse 
usually  occurring  between  an  axon  and  a  dendritic  spine  or  dendritic  shaft.  It  is 
generally thought that this type of synapses involve axons that contain predominantly 
spherical  vesicles  and  contain  a  thickened  postsynaptic  density  (PSD),  which 
renders  the  synapse  asymmetrical  (Figure  1B).  In  contrast,  the  type  II  synapses 
display the less identifiable postsynaptic density and the narrow cleft which does not 
contain a dense plaque, thus the overall configuration is symmetrical. In terms of 
physiological  typing,  neurobiological  studies  have  revealed  that  type  I  synapse  is 
excitatory, whereas the type II is inhibitory. 
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Figure 1. Illustration of a typical chemical synapse and ultrastructural features of the 
synapse.  A.The  image  illustrates  a  chemical  synapse,  the  major  pre-  and  post-synaptic 
elements  are  indicated.  Synapses  allow  nerve  cells  to  communicate  with  target  cells, 
converting electrical impulses into chemical signals. B. Electron photomicrograph of a mossy 
fiber  terminal  in  the  rat  hippocampus  making  contact  with  multiple  postsynaptic  neurons 
(Adapted from Gundelfinger and tom Dieck, 2000). Note the presynaptic terminal is stuffed 
with synaptic vesicles. The postsynaptic side is characterized by an even more prominent 
electron-dense structure, the postsynaptic density (PSD). Scale bars: 300 nm. 
 
Synaptic transmission is a process that allows nerve impulses are propagated from a 
neuron to a target cell at synapses by the release of neurotransmitters. As a nerve 
impulse, or action potential, reaches the end  of a presynaptic axon,  molecules of 
neurotransmitter are  quickly  and  efficiently  released into the synaptic cleft. These 
neurotransmitter then are recognized by selective receptors on the postsynaptic cell 
so  that  they  can  open  nearby  ion  channels  in  the  post-synaptic  cell  membrane, 
causing  ions  to  rush  in  or  out  and  changing  the  transmembrane  potential  of  the 
postsynaptic cell and initiate another action potential. After binding to the receptors, 
the neurotransmitter must be inactivated or removed rapidly from synaptic cleft so 
that the receptor sites of the postsynaptic cell will not be continually occupied and 
therefore avoids constant stimulation of the postsynaptic cell. 
For the removing of transmitters from synaptic cleft, neurons adopt special proteins 
called transporters to clear many transmitters by being taken up into the presynaptic   7 
terminals. This process is known as reuptake, reuptake system regulates synaptic 
activity precisely and also allows the terminal to recycle transmitter molecules. 
 
1.2. Glutamate 
 
The amino acid glutamate is considered the primary excitatory neurotransmitter in 
the mammalian central nervous system. In addition to acting as a key molecule in 
cellular  metabolism,  the  role  of  glutamate  as  neurotransmitter  is  now  well 
established, and excitatory processes mediated by glutamate are involved in most 
higher brain functions, including cognition, memory and learning. The glutamate that 
is present in the brain is mainly synthesized by astrocytes (Hertz et al., 1999), and 
glutamate  released  from  synaptic  vesicles  is  the  major  source  of  extracellular 
glutamate under normal physiological conditions. Glutamate is stored intracellularly 
and activates glutamate receptors only when actively released from nerve terminals. 
Studies  have  shown  that  the  efflux  of  cytosolic  glutamate  from  neurons  and 
astrocytes also can lead to an increase of glutamate levels in the cerebrospinal fluid 
and thereby cause disorders of nervous systems (Anderson and Swanson, 2000). In 
the  synaptic  cleft,  glutamate  mediates  neurotransmission  by  binding  to  glutamate 
receptors. Several subtypes of glutamate receptors have been identified: ionotropic 
glutamate  receptors  (NMDA,  AMPA  and  Kainate  receptors)  and  metabotropic 
glutamate  receptors    (Figure  2).  Since  the  maintanance  of  low  extracellular 
concentrations of glutamate is  essential for  brain function, neurons and  glial cells 
posess specialized glutamate  uptake systems,  e.g. glutamate transporter  proteins 
that remove excess glutamate (Shigeri et al., 2004).  
 
1.3. Glutamate receptors 
 
1.3.1. Ionotropic glutamate receptors 
 
The ionotropic glutamate receptors are ligand-gated ion channels that mediate the 
majority of excitatory neurotransmission in the vertebrate central nervous system. 
These  receptors  are  crucially  involved  in  development  and  in  different  forms  of 
synaptic plasticity, which may underlie learning and memory formation (Hollmann 
and  Heinemann,  1994;  McBain  and  Mayer,  1994).  Based  on  electrophysiologial   8 
studies,  three  distinct  classes  of  ionotropic  glutamate  receptors  have  been 
identified  and  named  after  the  agonists  NMDA  (N-methyl-D-aspartate),  AMPA 
(alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate)  and  Kainate.  The 
activation of ionotropic glutamate receptors increases transmembrane sodium and 
calcium  fluxes,  and  thereby  produce  depolarization  of  the  neuronal  membrane 
(Myers et al., 1999).  
 
1.3.1.1. AMPA receptors 
AMPA receptors are the glutamate gated channels which are responsible for most 
fast  excitatory  response  in  the  central  nervous  system.  Increasing  evidence 
suggests that AMPA receptors are tetrameric structures that combine homologous 
subunits  GluR1  to  GluR4  in  different  stoichiometries.  Most  AMPA  receptors  are 
either  homo-tetramers  of  GluR1  or  GluR4,  or  symmetric  ’’dimer  of  dimers’’  of 
GluR2/3 and either GluR1 or GluR4 (Wisden and Seeburg, 1993). 
AMPA receptors are mainly Na
+ permeable, but also flux Ca
2+.  Some subgroups of 
AMPA receptors lack  Ca
2+  permeability, which is due to posttranscriptional RNA 
editing of one of the AMPA receptor subunit. In the GluR2 mRNA, a single base 
pair  is altered so that the codon encodes an arginine (R) instead of a glutamine (Q) 
in  the  pore-forming  region.  The  editing  of  this  ´Q/R´    site    abolishes  the  Ca
2+ 
permeability of the AMPA receptor channel (Seeburg, 2002). 
AMPA  receptors  have  a  crucial  role  on  the  regulation  of  synaptic  efficacy  and 
postsynaptic  excitability.  The  trafficking,  density  and  degradation  of  AMPA 
receptors  are  therefore  tightly  regulated  in  neurons.  For  the  delivery  of  AMPA 
receptors  into  synapses,  two  distinct  pathways  seem  to  exist  (Borgdorff  and 
Choquet,  2002).  Multipe  studies  have  shown  GluR2-GluR3  oligomers  are 
constitutively inserted into synapses (Passafaro et al., 2001; Shi et al., 2001), while 
GluR1-GluR2 and GluR4- containing receptors are delivered to synaptic sites in an 
activity dependent manner (Zhu et al., 2000). The two pathways that control the 
synaptic  trafficking  of  AMPA  receptors  work  together  to  maintain  the  synaptic 
strength and plasticity. 
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1.3.1.2. NMDA receptors 
NMDA  receptors  are  heteromeric  proteins  composed  of  NR1,  NR2  and/or  NR3 
subunits (Schorge and Colquhoun, 2003). The NR1 subunit is encoded by a single 
gene that give rise to at least eight different splice variants (a-h), while the NR2 
subunits are the products of four different genes, NR2A-NR2D (McBain and Mayer, 
1994). More recently, NR3 subunits have been cloned and studied in heterologous 
expression systems, but their functions and distribution in the brain still need further 
characterization (Nishi et al., 2001; Yamakura et al., 2005). 
The NMDA receptor channel is permeable to various mono and divalent cations 
(Na
+,  K
+,  Ca
2+,  Ba
2+,  etc.);  however,  at  resting  membrane  potential,  the  NMDA 
receptor channel is blocked by Mg
2+ ions, membrane depolarizaton is required to 
remove the  Mg
2+  blockage  to  alow activation of channel  upon agonist binding 
(Mayer et al., 1984; Nowak et al., 1984; Danysz and Parsons, 1998). The NMDA 
receptor has distinct binding sites for different endogenous ligands  that regulate 
ion channel opening: glutamate, glycine, polyamine,  Mg
2+  and Zn
2+. For efficient 
opening of  the channel, binding of both glutamate and the co-agonist glycine is 
required (Johnson and Ascher, 1987). Additionally, the NMDA recepor channel is 
modulated by various compounds. For instance, Zn
2+ blocks the NMDA current in a 
non-competitive  and  voltage-independent  manner  (Berger  and  Rebernik,  1999), 
whereas  polyamine  potentiate  or  inhibit  glutamate  responses  (Kashiwagi  et  al., 
1997; Herin and Aizenman, 2004). 
NMDA receptors play a key role in a wide range of physiological and pathologic 
processes. It has been shown that activation of the  NMDA receptor is linked to 
long-term  potentiation  (LTP)  and  depression  (LTD),  as  well  as  neuronal 
development (Dingledine et al., 1999).  On the other hand, overactivation of the 
NMDA receptor is thought to account for different pathological processes, such as 
ischemia-induced excitotoxicity (Lee et al., 1999) and seizures (Loscher, 1998). 
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Figure  2.  The  general  synaptic  localization  of  glutamate  rceptors  at  a  typical 
excitatory  synapse  (Adapted  from  Enz  2007).  The  ionotropic  glutamate  receptors 
subtypes (NMDA, Kainate and AMPA receptors), mainly function to mediate fast synaptic 
transmission,  but  also  mediate  the  changes  required  for  neuronal  plasticity.  The 
metabotropic  glutamate  receptors  have  a  diverse  synaptic  localization,  mGluR1  and 
mGluR5  (group  I)  are  mostly  localized  postsynaptically,  mGluR4,  mGluR7  and  mGluR8 
(group  III)  at  the  presynapse,  while  mGluR2  and  mGluR3  (group  II)  do  not  show  any 
preference.  mGluR6  is  only  expressed  in  retinal  bipolar  cells  postsynaptic  to 
photoreceptors. Vesicles containing the neurotransmitter glutamate are shown in red, and 
the active zone is indicated by black boxes at the presynaptic terminal. 
 
1.3.1.3. Kainate receptors 
Kainate  receptors  and  AMPA  receptors  are  often  called  `non-NMDA  receptors`. 
Due to limited data on pharmacology and electrophysiology, kainate receptors are 
not  as  well  understood  as  the  other  ionotropic  glutamate  receptors.  So  far,  five 
kainate receptor subunits have been cloned, they are GluR5, GluR6, GluR7, KA1   11 
and KA2 (Hollmann and Heinemann, 1994). All these subunit share a conserved 
transmembrane topology with AMPA and NMDA receptor subunits.  GluR5, 6 and 7 
can  form  homomeric  and  heteromeric  receptors;  however,  KA1  and  KA2  only 
assemble into functional receptors in combination with one of the GluR5, 6 or 7 
subunits (Sommer et al., 1992; Madden, 2002). Kainate receptors have been found 
to  be  present  at  both  pre-and  postsynaptically.  The  activation  of  presynaptic 
kainate  receptors  modulates  transmitter  release  and  synaptic  transmission, 
whereas  postsynaptic  receptors  are  invoved  in  synaptic  plasticity  particularly  at 
mossy fibre synapses in the hippocampus (Lerma, 2003). 
 
1.3.2. Metabotropic glutamate receptors (mGluRs) 
Studies in the  1980s have shown that glutamate receptor activation can lead to 
phosphoinositide hydrolysis through GTP-binding proteins (Sugiyama et al., 1987). 
Subsequent analysis revealed that there is a large family of glutamate receptors, 
termed  metabotropic  glutamate  receptors  (mGluRs),  which  couple  to  second 
messenger  systems  via  G-proteins.  Like  all  family  C  GPCR  members,  mGluRs 
have a long extracellular N-terminus that is crucial for ligand binding and activation. 
In 1991, two groups isolated and cloned cDNA encoding the first mGluR (Houamed 
et  al.,  1991;  Masu  et  al.,  1991),  now  named  mGluR1a.  To  date,  eight  mGluRs 
family members have been cloned, classified into three groups (Table 1) based on 
sequence homology and pharmacology. mGluRs of the same group display about 
70%  sequence  identity,  whereas  between  groups  this  percentage  decreases  to 
about 45% (Conn and Pin, 1997). mGluRs belong to the G-protein coupled receptor 
(GPCR) superfamily, which can be divided in three subgroups (Pierce et al., 2002).  
Family  1  GPCRs  share  homology  with  the  rhodopsin,  including  acetylcholine, 
catecholamine,  glycoprotein  and  certain  peptide  receptors.  Family  2  receptors 
share  homology  with  secretin  receptors  that  includes  receptors  for  polypeptide 
hormones and a group of Drosophila proteins that regulate stress responses and 
longevity. The mGluRs belong to family 3 GPCRs, which also includes the gamma-
aminobutyric acid type  B (GABAB) receptors, the parathyroid hormone receptors 
and  Ca
2+-sensing receptors, as well  as putative taste, olfactory, and pheromone 
receptors.  Unlike  family  1  and  2  GPCRs,  whose  ligand  binding  sites  include 
portions of the transmembrane domain regions, the ligand binding site of family 3   12 
GPCRs is located within  a large  N-terminal domain  of approximately 500  amino 
acids. 
The  discovery  of  mGluRs  dramatically  expanded  the  understanding  of 
glutamatergic  neurotransmission  in  the  mammalian  CNS.  It  is  believed  that 
activation of mGluRs can modulate or fine-tune neuronal activity in glutamatergic 
circuits  (Conn  and  Pin,  1997).  Many  studies  have  shown  that  mGluRs  are 
ubiquitously distributed in the brain and participate in a wide variety of functions of 
the  CNS  (Swanson  et  al.,  2005).  Generally,  mGluRs  play  important  roles  in 
regulating neuronal cell excitability and synaptic transmission. Activation of mGluRs 
modulates  various  voltage-  sensitive  ion  channels,  and  may  also  stimulate 
intracellular  signaling  cascades  which  affect  synaptic  transmission,  synaptic 
integration, and plasticity (Conn, 2003). 
Group  I  mGluRs  (mGluR1/5)  are  predominantly  located  at  the  periphery  of  the 
postsynaptic  density  (Baude  et  al.,  1993;  Lujan  et  al.,  1997),  and  they  are 
expressed in many different brain regions. Activation of group I mGluRs results in 
phosphoinositide hydrolysis, calcium release and protein kinase C activation, and 
also causes postsynaptic depolarizaton and spike frequency adaption in a number 
of brain regions, such as hippocampus, cortex, striatum and hypothalamic nuclei 
(Keele et al., 1997; Schrader and Tasker, 1997). Different types of K
+ channels are 
major down-stream targets of group I mGluRs. Inhibiton of K
+ channels following 
activation of group I mGluRs leads to an increase in neuronal excitability. Voltage-
gated  calcium  channels  (VGCCs)  may  also  be  modulated  by  group  I  mGluRs 
(Sahara and Westbrook, 1993; Sung et al., 2001). It has been reported that group I 
mGluRs  can  use  distinct  signal  transduction  pathways  to  modulate  calcium 
channels (Lester and Jahr, 1990; McCool et al., 1998). Proper function of group1 
mGluR  requires  special  scaffolding  proteins,  termed  Homer  proteins.  Homer 
proteins  interact  with  group  I  mGluRs  via  the  C-terminal  tails  and  constitute 
components of postsynaptic densities  (PSD) (Xiao et  al., 2001).  Homer proteins 
also  link  mGluRs  to  intracelluar  calcium  stores  via  IP3  receptors  and  other 
scaffolding proteins such as Shank. Published data suggests that Homer proteins 
are involved in the physical coupling, synaptic targeting, and/or clustering of group I 
mGluRs, therefby regulating diverse functions of these receptors (Brakeman et al., 
1997).   13 
Table 1.  Classification of mGluRs 
 
Receptor  
family 
Coupling  Transduction  Group/subtype-selective phamacological 
agents 
Group I   
mGluR1  Gq-coupled 
(Excitatory) 
↑PLC 
 ↑Ca 
 
Agonists: DHPG, 1S, 3R-ACPD, quisqualate 
Antagonist: LY393675 allosteric antagonist: 
LY367385 
mGluR5  Gq-coupled 
(Excitatory) 
 
↑PLC 
 ↑Ca 
agonists: DHPG, 1S,3R-ACPD, quisqualate, 
CHPG allosteric antagonist: MPEP 
Group II   
mGluR2  Gi/Go-coupled 
(Inhibitory) 
adenylate 
cyclase 
 (AC) 
Agonists: DCG-IV, LY354730, 1S, 3R-ACPD  
Antagonist: LY341495 
mGluR3  Gi/Go-coupled 
(Inhibitory) 
adenylate 
cyclase 
(AC) 
Agonists: DCG-IV, LY354730, 1S, 3R ACPD  
Antagonist: LY341495 
Group III   
mGluR4  Gi/Go-coupled 
(Inhibitory) 
adenylate 
cyclase 
(AC) 
Agonists: L-AP4, L-SOP 
Antagonist: MSOP, MAP4 
mGluR6  Gi/Go-coupled 
(Inhibitory) 
adenylate 
cyclase 
 (AC) 
Agonists: L-AP4, L-SOP  
Antagonist: MSOP, MAP4 
mGluR7  Gi/Go-coupled 
(Inhibitory) 
adenylate 
cyclase 
(AC) 
Agonists: L-AP4, L-SOP  
Antagonist: MSOP, MAP4 
mGluR8  Gi/Go-coupled 
(Inhibitory) 
adenylate 
cyclase 
(AC) 
Agonists: L-AP4, L-SOP, 3,4-DCPG 
Antagonist: MSOP, MAP4 
Modified from Swanson et al., 2005 
 
 
Group II mGluRs (mGluR2/3) are widely distributed throughout the CNS (Sato et 
al.,  2004),  mGluR2  is  found  at  the  periphery  of  the  presynaptic  terminal,  while   14 
mGluR3 is more diversely localized,  at both pre- and postsynaptic sites, and on 
certain  glial  cells  where  its  functional  role  is  unclear  (Aronica  et  al.,  2005). 
Presynaptic group II mGluRs decrease the probability of synaptic vesicle release 
through a negative feedback  mechanism (Gereau  and  Conn,  1994);  in addition, 
postsynaptic functions have also been found at multiple synapses within the CNS 
(Heinbockel and Pape, 2000; Otani et al., 2002). Voltage-dependent Ca
2+ channels 
are likely to be involved in the presynaptic inhibition mediated by group II mGluRs. 
Additionally, it has been suggested that K
+ channels mediate some of the effects 
induced by activation of group II mGluRs (Anwyl, 1999). mGluR2 knockout mice 
have been generated and used to show that mGluR2 is a presynaptic modulatory 
receptor in the hippocampus (Yokoi et al., 1996). In mGluR2-deficient mice, long-
term  depression  induced  by  low-frequency  stimulation  of  the  mossy  fiber  CA3 
synapses  is  abolished,  thus  illustrating  an  important  role  of  mGluR2  in  the 
modulation  of  neuronal  excitability.  However,  these  knockout  mice  otherwise 
appear to be normal, with no alterations in basal synaptic transmission, suggesting 
that  mGluR2  do  not  play  a  prominent  role  in  the  acute  regulation  of  excitatory 
synaptic transmission (Yokoi et al., 1996). In addition, it has been shown that LTD 
can be induced by activation of group II mGluRs (Kahn et al., 2001; Kawasaki et 
al., 2004). Notably, group II mGluRs induce LTD presynaptically in the basolateral 
amygdala  (BLA),  the  nucleus  accumbens  (Robbe  et  al.,  2002)  and  the  striatum 
(Lovinger  and  McCool,  1995).  In  contrast,  stimulation  of  thalamic  inputs  to  the 
lateral nucleus of the amygdala induces a group II mGluR mediated postsynaptic 
LTD  (Heinbockel  and  Pape,  2000).  Furthermore,  in  the  dentate  gyrus  and  the 
medial region of the prefrontal cortex, group II mGluRs induce postsynaptic LTD 
that is PKA and PKC-dependent (Otani et al., 2002; Kawasaki et al., 2004). 
Group III mGluRs (mGluR4, 6, 7, 8) ainhibit cAMP production and modulate ion 
channels (Gereau and Conn, 1994). In contrast to other group mGluRs, group III 
mGluRs  are  primarily  located  at  presynaptic  active  zones  of  the  axon  terminal 
where they inhibit transmitter release (Shigemoto et al., 1996; Lujan et al., 1997). 
Unfortunately, only a limitted number of pharmacological tools with mGluR subtype 
selectivity  exists  to  exmine  the  functional  significance  of  individual  group  III 
receptors. L-AP4 is the most commonly used selective group III agonist; it has a 
high  affinity  for  mGluR4/6/8  and  a  low  affinity  for  mGluR7  (O'Hara  et  al.,  1993; 
Cartmell and Schoepp, 2000). More recently, 3, 4-DCPG and AMN082 have been   15 
described relatively specific agonists of mGluR8 and mGluR7, respectively (Linden 
et al., 2003b; Mitsukawa et al., 2005). 
Recently, the functions of distinct group III mGluR subtypes have been studied with 
knockout mouse models. These studies suggest that mGluR6 plays an important 
role  in  processing  of  visual  sensory  information  (Masu  et  al.,  1995).  mGluR6  is 
highly localized to dendrites of retinal ON bipolar cells, with very low expression in 
brain tissues. mGluR4 was found localized at both presynaptic and postsynaptic 
sites of different neurons, with high expression in cerebellum. mGluR4 knockout 
mice  show  deficits  in  motor-learning  tests,  and  in  electrophysioloical  studies, 
paired-pulse facilitation and post-tetanic potentiation were impaired in contrast to 
wild-type mice; additionally, the knockout mice were resistant to absence seizures 
induced  by  GABAA  receptor  antagonists  (Pekhletski  et  al.,  1996;  Snead  et  al., 
2000). mGluR8 is localized largely presynaptically on glutamatergic synapses, and 
highly  expressed  in  forebrain  regions.  mGluR8  knockout  mice  show  increased 
anxiety–like behavior and increased body weight (Linden et al., 2002; Linden et al., 
2003a).  mGluR7 is widely distributed in the brain, considered to be one of the most 
important  mGluR  subtypes  in  shaping  synaptic  responses  at  glutamatergic  and 
GABAergic synapses (Callaerts-Vegh et al., 2006), and will be discussed in great 
details in the subsequent section. 
 
1.4. Metabotropic glutamate receptor subtype 7 (mGluR7) 
 
1.4.1. Splice variants of mGluR7 receptors 
 
mGluR7  has  two  distinct  splice  variants  and  usually  named  mGluR7a  and 
mGluR7b (Figure  3). mGluR7a is considered the major isoform of  mGluR7, and 
extensive  studies  were  thus  dedicated  to  mGluR7a.  Later  on,  mGluR7b  was 
isolated from a human brain cDNA library and found to be conserved among other 
species, such as mouse and rat (Flor et al., 1997). The full length cDNAs of human 
mGluR7a and mGluR7b differ at the 3’ end of the coding region by an out-of-frame 
insertion of 92 nucleotides resulting in two putative proteins of 915 and 922 amino 
acids length. In mGluR7b, the last 15 amino acids of human mGluR7a are replaced   16 
by a novel sequence of 23 amino acids which have no sequence similarity to the C-
terminus of other mGluRs. Immunohistochemical studies in rat brain have shown 
that, at the protein level, mGluR7b is much less abundant than mGluR7a (Kinoshita 
et al., 1998). Pharmacological assays suggest CHO cells stably transfected with 
the  cloned  human  mGluR7b  cDNA  exhibited  L-AP4  induced  depression  of 
forskolin-stimulated cAMP accumulation (Flor  et al., 1997) and  human  mGluR7a 
and mGluR7b shows an identical rank order of potency and similar EC50 values for 
both L-SOP and L-AP4.  
 
 
  
Figure  3.  Two  splice  variants  of  mouse  mGluR7  (mGluR7a  and  mGluR7b).  A. 
Schematic  representation  of  the  two  mouse  mGluR7  splice  variants,  mGluR7a  and 
mGluR7b.  Seven  transmembrane  regions  are  indicated  by  numbered  black  boxes,  the 
splice-specific regions are located in the C-terminus, note the different sequence for the last 
26  amino  acids  of  mGluR7a  and  mGluR7b.  B.  Alignment  of  the  C-terminal  end  of  the 
mouse mGluR7a and mGluR7b cDNA sequences and the deduced amino acid sequences 
in  single  letter  code  (modified  from  Flor  et  al.,  1997).  Out-of-frame  insertion  of  92 
nucleotides into mGluR7a C-tail results in putative proteins of mGluR7b. 
   17 
Kinases, phosphatases and structural proteins have been shown to associate with 
mGluR7b  and  to  regulate  mGluR7  mediated  neurotransmission  (Enz  and  Croci, 
2003).  Compared with mGluR7a, mGluR7b shares some of the known interacting 
proteins in the intracellular C-terminal region. 
Recently,  it  was  reported  that  three  putative  novel  isoformes  of  mGluR7  were 
identified  based  on  splicing  events  involving  the  3’  end  of  the  mGluR7  coding 
sequence  (Schulz  et  al.,  2002).  The  new  isoforms  might  be  expressed  in  non-
neuronal  tissues.  However,  these  results  were  never  confirmed  by  in-situ 
hybridization,  immunohistochemistry  or  functional  analysis.  Additional  data  are 
needed to confirm the existence of these novel isoformes of mGluR7. 
 
1.4.2. Localization of mGluR7 mRNA and protein in the mammalian CNS 
 
Both  in  situ  hybridizaton  and  immunocytochemistry  have  been  performed  to 
disclose the distribution of mGluR7 mRNAs and proteins in the mammalian CNS.  
Due to the antibody quality, more data are avaiable for mGluR7a, while mGluR7b is 
less well explored. Quite a few studies showed that mGluR7a immnoreactivity is 
widely distributed throughout the adult rat and/or mouse brain (Kinzie et al., 1997; 
Bradley et al., 1998; Kinoshita et al., 1998; Kosinski et al., 1999).  mGluR7a protein 
levels are particularly high in sensory areas, such as piriform cortex and entorhinal 
cortex, superior colliculus, dorsal cochlear nuclears, olfactory bulbs, and high in the 
hippocampus,  thalamic  reticular  nucleus,  corpus  striatum,  globus  pallidus,  and 
facial nerve, In contrast, mGluR7a immunostaining was rarely detected in medial 
septal nucleus, ventromedial nucleus, ventral tegmental area, oculomotor nucleus, 
and cerebellar nuclei (Kinoshita et al., 1998). 
In neocortical regions, mGluR7a antibody staining shows a diffuse distribution. In 
cortex, it was intense in layer I, moderate in layers II, III, and V, and weak in layers 
IV  and  VI.  In  the  amygdala,  intense  to  moderate  mGluR7a  was  seen  in  the 
periamygdaloid  cortical  regions.  The  amygdala-hippocampal  area  also  displayed 
intense  to  moderate  mGluR7a  distribution.  In  the  CA1  region  of  hippocampus, 
imGluR7a  signals  were  intense  in  the  stratum  oriens  and  stratum  radiatum  and 
moderate in the stratum lacunosum-moleculare; no mGluR7a staining was seen in   18 
the  stratum  pyramidale.  In  CA3,  mGluR7a  staining  was  intense  in  stratum 
lacunosum-moleculare, moderate in the stratum radiatum and stratum oriens, and 
weak in the stratum lucidum; In the dentate gyrus, mGluR7a was intense in the 
molecular  layer;  no  mGluR7a,  however,  was  seen  in  the  granule  cell  layer 
(Kinoshita et al., 1998).  
 
1.4.3.  mGluR7  and  its  implicatons  for  signal  transduction  and  synaptic 
transmission 
 
As all group III mGluRs, mGluR7 has been shown to modulate second messenger 
systems and ion channels. mGluR7 inhibit forskolin stimulated adenylate cyclase 
activity in various cell lines and brain slices (Okamoto et al., 1994; Wu et al., 1998). 
This  effect  is  pertussis  toxin  (PTX)-sensitive,  implying  an  interaction  with  Gi/o 
proteins.  In  different  brain  tissues,  selective  group  III  mGluR  agonists  decrease 
Ca
2+  currents  via  the  inhibition  of  L-type,  and  P/Q-type  voltage-sensitive  Ca
2+ 
channels (Trombley and Westbrook, 1992; Herrero et al., 1996; Takahashi et al., 
1996). This decrease in Ca
2+ current is PTX-sensitive and involves protein kinase 
C.  The group III mGluRs selective agonist L-AP4 has also been shown to couple 
mGluR7 to recombinant G-protein inwardly rectifying potassium channels (GIRK) in 
Xenopus  oocytes  (Saugstad  et  al.,  1996).  The  localization  of  mGluR7  at 
presynaptic  nerve  terminals,  combined  with  its  negative  coupling  to  adenylate 
cyclase  and  voltage-sensitive  Ca
2+  channels,  suggest  a  role  for  mGluR7  as  an 
autoreceptor  that  inhibits  neurotransmitter  release.  Different  studies  have 
demonstrated  that  group  III  agonists  decrease  synaptic  transmission  at 
glutamatergic  synapses  located  in  the  hippocampus,  olfactory  bulb,  cerebellum, 
and the thalamus (Schoppa and Westbrook, 1997; Perroy et al., 2000; Panatier et 
al., 2004). 
More recently, the functional role of  mGluR7  has been further investigated,  and 
new data suggest that mGluR7 may play an important role in regulating synaptic 
transmission and plasticity.  
Bough et al. (2004) studied the function of mGluR7 by performing experiments in 
hippocampal slices prepared from mGluR4/8 double knockout mice, In the medial   19 
perforant path (MPP), L-AP4 (600µM) reversibly reduced the fEPSP slope equally 
in  slices  taken  from  either  wild-type  or  mGluR4/8  double  knockout  mice.  In  the 
lateral perforant path (LPP) of animals, L-AP4 (600 µM) suppressed fEPSPs by 40 
± 3% in slices taken from  wild-type  mice, however, L-AP4 only slightly inhibited 
responses  in  mGluR4/8  double  knockout  animals.  This  suggests  that  mGluR7-
mediated presynaptic inhibition is functionally limited to the MPP, but not the LPP, 
which  is  consistent  with  the  notion  that  a  reduction  of  mGluR7  function  may 
contribute to epileptogenesis (Bough et al., 2004). In the other elegant work, Pelkey 
et al. (2005) investigated the mossy fiber synaptic transmission and found that the 
bidirectional  plasticity  of  mossy  fiber–stratum  lucidum  feedforward  inhibition  was 
controlled by mGluR7. Their experiments on the mice brain slices have shown that 
the  presynaptically  located  mGluR7,  whose  activation  and  surface  expression 
governs  the  direction  of  plasticity,  is  a  metaplastic  switch  at  MF  (hippocampal 
mossy fiber)-SLIN (CA3 stratum lucidum interneurons) synapses. In naive slices, 
mGluR7 activation during high-frequency stimulation generates MF-SLIN long-term 
depression  (LTD),  depressing  presynaptic  release  through  a  PKC-dependent 
mechanism.  Moreover,  following  agonist  exposure,  mGluR7  undergoes 
internalization, unmasking the ability of MF-SLIN synapses to undergo presynaptic 
potentiation in response to the high frequency stimulation that induces LTD in naive 
slices. Thus, selective mGluR7 targeting to MF terminals contacting SLINs and not 
principal  cells  provides  cell  target–specific  plasticity  and  bidirectional  control  of 
feedforward inhibition (Pelkey et al., 2005). 
 
1.4.4. The role of mGluR7 in epilepsy and seizures 
 
Epilepsy is a chronic neurological disorder characterized by large populations of 
neurons in selected portions of the CNS showing increased activity and begining to 
fire  in  periodic,  synchronous  discharges.  The  defining  phenotypic  feature  of 
epileptic syndromes is the seizure. Seizure phenotypes are quite diverse, ranging 
from electrographic seizures with no obvious behavioral symtoms, to generalized 
seizures with severe motor convulsions and impaired consciousness (Doherty and 
Dingledine, 2002).  Increasing evidences suggest that mGluRs are linked to the 
etiology and therapy of epilepsy (Ghauri et al., 1996; Klapstein et al., 1999; Barton   20 
and Shannon, 2005), however, only the potential role of mGluR7 in epilepsy and 
seizure generation will be discussed here. 
The first evidence for a role of mGluR7 in seizures came from in vivo studies. The 
agonist L-AP4 for mGluR7, when focally injected into the hippocampus, effectively 
suppressed  amygdala-kindled  seizures  (Abdul-Ghani  et  al.,  1997).  On  the  other 
hand, the group III mGluR  agonist also increases the  latency to  pentylenetrazol 
(PTZ)-induced seizures in mice (Thomsen and Dalby, 1998). Additional support for 
a role of mGluR7 in epilepsy came from mGluR7 knockout mice. 
mGluR7 knockout mice were first described by Masugi et al. (Masugi et al., 1999). 
These mice develop seizures after 12 weeks of age, especially when placed in a 
novel environment. Sansig et al. confirmed (Sansig et al., 2001b) that tonic-clonic 
seizures  are  triggered  in  adult  (>12  weeks)  mGluR7-deficient  mice  when  the 
animals are exposed to new bedding. In another set of experiments, the authors 
could show that homozygous mutant mice, but not heterozygous mice or wild-type 
mice  had  a  lowered  threshold  for  bicuculline-induced  seizures  (Sansig  et  al., 
2001b).  However,  these  mice  did  not  display  spontaneous  seizures,  suggesting 
mGluR7  gene  ablation  result  in  an  increased  susceptibility  to  sensory  and 
chemoconvulsant-induced seizures. 
 
1.4.5. mGluR7 interacts with PICK1 (Protein Interacting with C Kinase 1) 
 
The  identification  of specific  proteins that  interact with the  C-terminal domain  of 
mGluR7 receptors has been investigated during the last decade in different labs, 
and considerable progress has been made towards understanding the mechanisms 
that underlie the regulation, signal transduction pathways and targeting of mGluR7 
receptors (Dev et al., 2001). Yeast two-hybrid screens using the C-terminal tail of 
mGluR7 as ‘’bait’’ revealed a direct interaction of mGluR7 with PICK1 (Boudin et 
al., 2000; Dev et al., 2000; El Far et al., 2000). PICK1 has originally been described 
as a PDZ (PSD-95/Dlg1/ZO-1) domain-containing protein that interacts with and is 
phosphorylated  by PKCα (Staudinger  et al., 1995; Staudinger et al., 1997). The 
previous  work  in  our  lab  has  shown  that  the  protein  kinase  C  substrate  PICK1 
interacts  with  the  major  cytoplasmic  domain  of  mGluR7a.  PICK1  binding  is   21 
mediated by the extreme C-terminus of the receptor, the replacement of the last 
three  amino  acids  leucine,  valine  and  isoleucine  of  mGluR7a  by  alanines 
decreased the intensity of the interaction. Similarly, the integrity of the PICK1 PDZ 
domain proved crucial for this interaction. Substitution of residues K27 and D28 in 
the carboxylate binding loop  of PICK1 by alanines prevented its interaction  with 
mGluR7a (Boudin et al., 2000; Dev et al., 2000; El Far et al., 2000). It is relatively 
clear that the interaction of mGluR7a with PICK1 is based on a conventional PDZ 
domain–C-terminal  peptide  interaction  (Figure  4).  Based  on  binding  specificities 
and  sequence  homologies,  PDZ  domains  are  classified  into  three  types.  Type  I 
sequences select for peptides with the C-terminal consensus motif [-S/T-X-Φ (X: 
unspecified  amino  acid;  Φ:  hydrophobic  amino  acid)]  (Songyang  et  al.,  1997), 
whilst type II PDZ domain, specific for -X-Φ-X-Φ sequences, is characterized by 
hydrophobic  residues  at  both  the  -2  position  of  the  peptide  ligand  and  the  αB1 
position of the PDZ domain. As for type III PDZ domain, it is specific for a different -
X-D/E-X-Φ pattern, and prefers negatively charged amino acids at the -2 position 
(Stricker et al., 1997). When considering these characteristics and comparing the 
primary sequence of the PICK1 PDZ domain with those of different members of 
types I, II and III PDZ motifs, it is difficult to classify the PICK1 PDZ domain into 
particular subtypes. Since PDZ domain of PICK1 could mediate interactions with 
PKCα through type I peptide ligand (DSSL) and with GluR2 through type II peptide 
ligand (SVKI), It could be therefore proposed that this PDZ region specifies a new 
type of PDZ domains. 
   22 
 
Figure 4. The specific interaction between mGluR7a and PICK1. PICK1 is a single PDZ-
domain containing protein, the interaction of mGluR7a cytoplasmic domain with PICK1 is 
based  on  a  conventional  PDZ  domain–C-terminal  peptide  interaction,  the  PDZ-domain 
binding motif is located in extreme C-terminal region of mGluR7a. 
 
In addition to binding PKCα, PICK1 serves as a scaffolding protein for presynaptic 
mGluRs. Strong evidence exists that the interaction with PICK1 is crucial for the 
clustering of mGluR7 at presynaptic release sites. Boudin et al. (2000) reported, in 
transfected hippocampal neurons, both wild-type and C-terminally mutated mGluR7 
lacking the last three amino acids required for PICK1 binding were targeted equally 
well  to  axons;  however,  only  the  wild-type,  and  not  the  mutant  receptor  was 
clustered presynaptically.  Both the coiled-coil regions of PICK1 and the PDZ motifs 
were found to be important for the presynaptic enrichment of PICK1, as mutation of 
the PDZ domain and deletion of the coiled-coil regions abolished co-clustering of 
PICK1 with mGluR7 in transfected hippocampal cultures (Boudin et al., 2000).   23 
Perroy  et  al.  (2002)  have  investigated  the  functional  consequences  of  the 
mGluR7a-PICK1 interaction in cultured cerebellar granule neurons and found that 
PICK1 is required for the specific inhibition of P/Q-type Ca
2+ channels (Perroy et al., 
2002). Furthermore, they could show that activation of mGluR7a receptor inhibits 
synaptic  transmission  and  that  this  effect  requires  the  presence  of  PICK1. 
Therefore, they concluded that PICK1 plays an essential role in mGluR7a receptor 
signaling rather than merely receptor clustering (Perroy et al., 2002). 
 
1.5. Aim of this thesis 
 
As outlined above, the goals of our laboratory are to elucidate the biochemical and 
physiological  functions  of  protein-protein  interaction  of  Group  III  mGluRs  in  the 
mammalian CNS. To this end, intracellular binding partners to group III mGluRs 
were  identified  and  related  signalling  processes  at  central  synapses  were 
ingestigated at different levels. My thesis project focused on the protein interaction 
between  mGluR7  and  the  PDZ-domain  protein  PICK1,  which  was  identified  by 
Yeast Two-Hybrid analysis. Preliminary data has indicated that PICK1 might be a 
potential  mGluR7  clustering  molecule  or  alternatively  alter  signal  transduction 
through a protein kinase C dependent pathway. However, the precise physiological 
roles  of  mGluR7-PICK1  interaction  are  still  poorly  understood,  and  no  detailed 
functional analysis has been performed so far because of the lack of suitable in 
vitro  assays.  The  best  insights  into  the  physiological  functions  of  this  protein 
interaction could be  provided by genetic approaches. Gene targeting technology 
allows to introduce any kind of specific mutation into the genome of the mouse by 
homologous  recombination  in  embryonic  stem  cells  (ES  cells).  The  aim  of  this 
thesis was the generation of a mouse strain which carries a mutation and disrupts 
the specific inteaction between mGluR7a and PICK1. The generated mice provide 
an animal model to study how the intracelluar binding proteins regulate the function 
of mGluR7; moreover, the control of synaptic trafficking and targeting of mGluR7 by 
PDZ  protein  will  be  investigated  in  more  detail,  and  mGluR7  mediated  synaptic 
transmission mechanism will be further studied using this mutant mouse, it will also 
provide a tool to dissect the molecular mechanism of excitatory neurotransmission 
of group III mGluRs in the brain.   24 
 
2. Material and Methods  
 
2.1. Materials 
 
2.1.1. Organism 
 
Mouse 
MTK-neo  CD1  transgenic  mice  were  used  for  preparation  of  mouse  embryonic 
fibroblast (MEF) feeder cells. 
 
The C57BL6 mouse line was used for backcrossing and maintaining the mGluR7 
Knock-in mouse line. 
 
Bacterial strain 
 
E. coli XL-1 blue,  Genotype:   recA1  endA1  gyrA96 thi-1  hsdR17. supE44 relA1 
lac[F‘ proAB lacI. q. Z M15 Tn10(Tet. R.)] 
 
E. coli DH5α, genotype: supE44 deltalacU169 (phi80 lacZ deltaM15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 
 
ES cell  
The SV129/Ola ES cell line (E14) was used to generate the mutant mouse model 
described in this thesis. 
 
2.1.2. Chemicals   25 
All  the  chemicals,  unless  otherwise  stated,  were  purchased  from  the  following 
firms:  Roche  Diagnostic    (Heidelberg,  Germany),  Fluka  (Taufkirchen,  Germany), 
Invitrogen  (Karlsruhe,  Germany),  Merck  Biosciences  (Schwalbach,  Germany), 
Sigma  –Aldrich-Chemie  (Taufkirchen,  Germany)  and  Roth  Carl  (Karlsruhe, 
Germany).  Water  used  to  make  solutions  was  prepared  with  a  Milli-Q-Water-
System  (Millipore,  Schwalbach,  Germany).  Restriction  enzymes  were  purchased 
from Roche Diagnostic (Heidelberg, Germany), or New England Biolabs (Frankfurt, 
Germany). 
 
2.1.3. Medium and antibiotics for Bacterial culture 
 
LB-Medium (Luria-Bertrani)  
Bacto-trypton 10 g/l 
Yeast-extract 5 g/l 
NaCl 10 g/l 
pH 7.5 
 
LB-Agar  
Bacto-trypton 10 g/l 
Yeast-extract 5 g/l 
NaCl 10 g/l 
Agar 15 g/l   
pH 7.5 
 
Antibiotics ( diluted 1:1000 in medium upon use) 
Ampicillin                       Stock 100mg/ml in H2O 
Kanamycinsulfate           Stock 50mg/ml in H2O 
Chloroamphenicol           stock 20mg/ml in methanol   26 
 
2.1.4.  Medium  and  supplements  for  Embryonic  stem  (ES)  cells  and  mouse 
embryonic fibroblast (MEF) feeder cells 
 
ES-Medium  
Dulbecco’s Modified Eagles Medium, high glucose 
L-Glutamin 2 mM 
Penicillin 100 U/ml 
Streptomicin 100 µg/ml 
Non-essential amino acids 0.1 mM 
Mercapto-ethanol 0. 1mM 
Heat inactivated ES-tested Fetal Bovine Serum 20%(v/v) 
Leukemia Inhibitory Factor (LIF) 1000 IU/ml 
 
The  medium  was  sterilized  through  filtration  with  a  0.22  µm  Bottle  Top  Filter 
(Becton Dickinson) and used for no longer than 2 weeks. 
 
ES-medium for double selection 
ES-medium  
Geneticin (G-418) 0.2 mg/ml 
2-Deoxy-2-Fluoro-β- D-arabinofuranosyl-5-iodouracil (FIAU) 0.2 µM 
 
MEF-medium  
DMEM 
Heat Inactivated Fetal Bovine Serum 10% (v/v) 
Penicillin 100 U/ml   27 
Streptomicin 100 µg/ml 
L-Glutamin 2 mM 
 
ES-freezing medium  
ES-medium 
Dimethyl-sulfoxide(DMSO)  
10% (v/v) 
 
MEF-freezing Medium 
 MEF-medium 
DMSO 10% (v/v) 
 
2.1.5. Medium and supplements for primary culture of Hippocampal neurons 
 
Hippocampal medium 
L-Glutamin 2 mM 
Penicillin 50 U/ml 
Streptomicin 50 µg/ml 
0.23mM sodium pyruvate 
2% B27 
Neurobasal medium 
 
2.1.6. General buffers and solutions 
 
10X PBS  
1.3M NaCl   28 
70mM Na2HPO4 
30mM NaH2PO4, pH 7.2 
 
Buffer  P1 (resuspension buffer) 
Tris/HCl 50 mM  
EDTA 10 mM  
RNase A 100 µg/ml  
pH 8.0  
 
Buffer P2 (lysis buffer)  
NaOH 200 mM  
SDS 1% (w/v)  
 
Buffer P3 (neutralization buffer) 
 Potassium--acetate 3M, pH 5.5  
 
1X MOPS  
0.418%  MOPS 
2mM  Na-Acetate 
1mM EDTA pH8.0 
 
20xSSC 
NaCl 3 M 
Na-Citrate 0.3 M 
pH 7.0 
   29 
Separating gel  
Acrylamide/bisacrylamide 7.5-15% (v/v) 
Tris/HCl 0.375 M 
SDS 0.1% (v/v) 
10% Ammonium-persulfate (APS, w/v) 4 µl/ml 
N,N,N’,N’-Tetramethyl-ethylenamin (TEMED) 0.72 µl/ml 
pH 8.8 
 
Stacking gel  
Acrylamide/bisacrylamide 7.5-15% (v/v) 
Tris/HCl 0.125 M 
SDS 0.1% (v/v) 
APS 6 µl/ml 
TEMED 0.72 µl/ml 
 
10 x Running Buffer  
Tris/HCl 0.25 M 
Glycin 1.92 M 
SDS 1% (v/v) 
 
Transfer Buffer (western-blot) 
Tris-HCl 200 mM 
Glycine 1,54 M 
SDS 0.8% (w/v) 
Methanol 20% (v/v) 
   30 
Poinceau Solution  
Poinceau S 0.3% (w/v) 
Tricloroacetic Acid 3% (w/v) 
 
4x Sample buffer for non-reducing conditions:  
4ml                10% SDS 
16.ml             1M Tris pH6.8 
2ml                glycerol 
1.9ml             H2O 
0.1%              bromophenol blue 
 
4x Sample buffer for reducing conditions:  
50µl β-mercaptoethanol /ml 4x sample buffer 
 
 
2.1.7. Plasmids and BAC clones 
 
Cloning vector  pBluescript II SK(+)  Stratagene 
  pBluescript II SK(-)  Stratagene 
  pEasy-Flox  Werner Müller, Institute of Genetics, 
University of Köln 
Cre-recombinase 
expression vector 
pPGKcrebpA  Werner Müller, Institute of Genetics, 
University of Köln 
mGluR7 gene 
containing clone 
BAC RP23-391F16  BACPAC resources center, 
Children’s Hospital Oakland, USA 
   31 
 
2.1.8. Oligonucleotides 
 
All oligonucleotides were ordered from MWG Biotech and disolved in HPLC water. 
Name   Sequence (5’—3’)   Special features 
Primer1  GCCAAAGTGTATGTGTATTCCTC 
Primer2  TCCATCACAACACCTACCATGTAC 
BAC clone 
identification 
Primer3  GTATGTCAGTTATAATAACGCAGCTGCCTAACCTGTTCC
ATCCC 
Primer4  GGGATGGAACAGGTTAGGCAGCTGCGTTATTATAACTG
ACATAC 
Site-directed 
Mutagenesis 
 
Primer5  GCCTTATCCAGGGATCCACCC 
Primer6  GCAGGATCCATTTATTTTGTCTGGCTGAG 
Short arm 
amplification 
Primer7  CTGAAGTGTGGACACTATGCCCCTC 
Primer8  GCTACTTCCATTTGTCACGTCCTGC 
ES clone screening 
Primer9  GCAGAGTTGGGAGTGAGACAGCTCAG 
Primer10  CTACATGTATGAATATGTACCATATGG 
External probe 
amplification 
Primer11  GAATTCCAATGACACAGGACATC 
Primer12  GATAGAGCGTGGATGATTTCCAG 
Internal probe 
amplification 
Primer13  GCCATTGTCAAGTACACATGACAAAGAG 
Primer14  CCGGGGGATCCACTAGATAACTTCGTA 
ES clone 
characterization 
Primer15  CCTGTAGATGCACTCAGCCAGACA 
Primer16  TTCCATGGGATGGAACAGGTTAGGC 
ES clone 
characterization 
Primer17  CCACCCTGAACTCAATGTCCAGAAAC  RT-PCR   32 
Primer18  GAGAAGCTCCTCCAGAGATAGGAAGC 
 
Primer19  CCACCCTGAACTCAATGTCCAGAAAC 
Primer20  TTAGATAACCAGGTTATTATAACTGACATAC 
Northern probe 
amplification 
Primer21  CCAGTGTGATTGTTCAGACATCGGAAAG 
Primer22  CCAGCCCTAAGCTGCAAAGGTGATCTGG 
Mice genotyping 
 
2.1.9. Antibodies 
 
Primary antibodies 
Name  species  Western blot  Immunostaining  supplier 
mGlur7,  
C-terminal 
Rabbit polyclonal  1:4000  1:200  Upstate, 
NY,USA 
mGluR4,  
N-terminal 
Rabbit polyconal  1:2000  -  Upstate 
NY, USA 
PICK1  Rabbit policonal  1:1000  -  Richard 
Huganir 
PICK1  Goat Polyclonal  1:500  -  Santa Cruz 
Biotechnolo-
gy, Inc. 
Synapsin  Mouse monoclnoal  -  1:400  Synaptic 
systems 
β-tubulin  Mouse monoclonal  1:2000  -  Sigma 
 
 
 
 
 
   33 
 
Secondary antibodies 
Name  dilution  supplier 
HRP α Mouse  1:5000  Promega, Madison USA 
HRP  α Rabbit  1:5000  Promega, Madison USA 
Alexa 488 α Rabbit  1:500-1:1000  Molecular probes, Eugene, USA 
Alexa 546 α Mouse  1:500-1:1000  Molecular probes, Eugene, USA 
Alexa 546 α Ginny- Pig  1:500-1:1000  Molecular probes, Eugene, USA 
 
2.1.10. Commercial Kits for molecular biology 
 
For standard molecular biology experiments, commercial kits were employed and 
all the protocols were performed according to the manufacturer’s instructions 
Qiagen Plasmid Kits (Mini, Midi, Maxi)  Qiagen 
Qiaquick Gel Extraction kit  Qiagen 
Qiaquick PCR Purification Kit  Qiagen 
ABI PRISM dye Terminator cycle sequencing Ready Reaction Kit  Perkin Elmer Applied 
Biosystems 
QuickChange Site-Directed mutagenesis Kit  Stratagene 
QuickHyb Rapid hybridization Solution  Stratagene 
Advantage GC cDNA PCR Kit  Clontech 
Prime-a -Gene Labeling System Kit  Promega 
ThermoScript RT-PCR system  Invitrogen 
 
   34 
2.2. Methods 
 
2.2.1. Biochemistry and molecular biology methods 
 
2.2.1.1. Preparation of DNA 
 
Small scale preparation of Plasmid DNA by alkaline lysis 
 
Cultures of 2 ml LB-medium containing selection antibiotics were prepared from a 
single colony and incubated overnight at 37 °C. Bacteria were pelleted at 8000 rpm 
for 1 min, resuspended in 100 µl of Buffer 1, and lysed by adding 200 µl of Buffer 2. 
After incubation for 5 min at room temperature, 150 µl of Buffer 3 were added to the 
lysate, gently mixed, incubated at 4 °C for 10 min and centrifuged at 13000 rpm for 
5  min.  The  supernatant  was  transferred  to  another  tube  and  the  DNA  was 
precipitated  with  2  volumes  of  ethanol,  pelleted  by  centrifugation  for  15  min  at 
13000 rpm, washed once with 70% ethanol and then resuspended in TE buffer. 
 
Mini, Midi and Maxi preparatons of plasmid DNA with Qiagen Kits 
 
Qiagen  Plasmid  Purification  kits  were  used  for  preparation  of  plasmid  DNA 
according  to  the  scale  of  bacterial  culture.  All  the  protocols  were  performed  by 
following the manufacture’s instructions. 
 
DNA isolation from BAC clone 
 
BAC DNA cultures (500ml) was incubated overnight at 37°C with antibiotics. The 
cells were pelleted at 3000 rpm for 15 min at 4°C and then resuspended in 15 ml of 
GTE (0.9% glucose, 25 mM Tris, pH 8, 10 mM EDTA, 0.1 mg/ml RNaseA). After 5 
min at R/T, 15 ml of fresh SDS/NaOH (1% SDS and 200 mM NaOH) were added,   35 
the cell lysate were mixed gently and then 20 ml of ice-cold KAc (3M potassium 
acetate made up in 2M acetic acid) were added immediately. The samples were 
mixed very gently, placed on ice for 20 minutes, and then centrifuged at 3000 rpm 
for 30 min at 4°C, the supernatant was transfered to clean tubes, the DNA was 
precipitated with 0.7 volumes of Isopropanol  and  the pellet was washed once with 
70%  ethanol.  The  pellet  was  dissolved  in  1ml  TE.  The  resuspended  pellet  was 
treated two times with phenol/chloroform, then 200ul 3M NaOAc and 0.7 volumes 
Isopropanol were added to precipitate the DNA, the DNA was washed with 70% 
EtOH; finally, 500ul TE was used to resuspend the DNA. 
 
Preparation of Genomic DNA from ES Cells in 24-well tissue culture plates 
 
Medium were removed from each well containing nearly confluent ES cells, cells 
were rinced once with PBS, then 400µl lysis buffer (150mM NaCl, 2mM EDTA, 1% 
SDS, 20mM Tris-HCl, pH 8.0) were loaded to each well, the dish was incubated for 
1h  at  37°C,  all  the  lysate  were  transfered  to  1.5  ml  eppendorf  tubes,  100µl 
saturated NaCl were added to each tube and shaked vigorously. The tubes were 
centrifuged at 3000g for 15min, the supernatant containing DNA were transfered to 
a fresh tube and added 2 volumes of ethanol at room temperature, the tube was 
inverted several times untill the DNA precipitate and then DNA was removed with a 
glass rod, the DNA pellet was washed in 70% ethanol and resuspended in 80µl TE 
and dissolved overnight at room temperature. 
 
Preparation of Genomic DNA from mouse tails 
 
Mouse tails were incubated with 500µl lysis buffer (Tris/HCl 100 mM, pH 8.5, EDTA 
5mM pH 8.0, NaCl 200 mM, 0.5% SDS (v/v), proteinase K 0.2mg/ml) overnight at 
55°C on shaker. After centrifugation for 30 min, supernatant was collected into a 
new 1.5ml tube, 500µl each of phenol and chloroform were added to the tubes. the 
samples were mixed by inversion and spun for 10 min. Upper layer was transfered 
into a new 1.5ml tube, 600µl Isopropanol was added, then mixed and span for 5   36 
min. The pellet was washed with 500µl 70% EtOH, and was allowed to air dry and 
finally dissolved in100µl TE. 
 
2.2.1.2. Total brain RNA preparation and RT-PCR 
 
The TRIzol Reagent (Invitrogen) was used to prepare the total RNA from mouse 
brain tissue, the frozen mouse brain tissue were placed in TRIzol Reagent (1 ml of 
TRIzol  Reagent  per  50-100  mg  of  tissue)  and  the  tissue  was  homogenized  at 
moderate speed, the homogenized samples were  incubated for 5 min at R/T, then 
0.2 ml of chloroform per ml of TRIzol Reagent were added, and incubated for 2-3 
min at R/T, the 500 µl (up to 750 µl) homogenates aliquots were transfered to a 
new  tube  and  were  centrifuged  for  15  min  at  12,000  rpm  at  4
 
°C.    The  upper 
colorless aqueous phase remaining the RNA were collected into a fresh tube. RNA 
was precipitated with 0.5 ml Isopropanol per ml of TRIzol Reagent by centrifugation 
at 12,000 rpm for 10 min at 4
 
°C. The supernatant was removed carefully, and the 
pellet was washed with 1 ml 75% ethanol, the RNA pellet was air-dried for 10 min 
and dissolved in 50 µl RNase-free water. 
Reverse  transcription  reaction  was  performed  with  the  ThermoScript  RT-PCR 
system (Invitrogen). All procedures followed the manufacturer’s instructions. Briefly, 
2 µg total RNA were added to 200 ng gene specific primers and 10mM dNTP mix, 
incubated at 65 °C for 10min, chilled on ice for 1 min. Then the reaction mixture (1X 
cDNA synthesis buffer, 100mM  DTT, RNaseOUT,  DEPC-H2O,ThermoScript  RT), 
was  added  and  incubated  at  50  °C  for  60  min,  the  reaction  was  terminated  by 
incubating at 85 °C for 5 min, then 2 units of RNase H were added and incubated at 
37 °C for 20 min. the cDNA synthesis reactions was used immediately for PCR. 
 
2.2.1.3. Site-directed mutagenesis 
 
Mutations were introduced using the QuickChange Site-Directed Mutagenesis Kits 
(Stratagene).  This  method  is  highly  effective  and  simple  for  introducing  site- 
directed  mutations  into  plasmids  without  subcloning.  Pfu  DNA  polymerase,  two   37 
synthetic oligonucleotide primers containing the desired mutation, and supercoiled 
double-stranded  DNA  vector  were  employed  for  the  basic  procedure.  After 
amplification  of  the  mutant  DNA,  the  product  was  treated  with  Dpn  I,  and  the 
mutation-containing synthesized DNA was selected by transforming to competent 
XL1-Blue cells. The reactions for amplification of mutant DNA were prepared as 
following: 
 
DNA template plasmid 20 ng 
10x pfu DNA polymerase buffer 5.0 µl 
125ng primer1 0.5 µl 
125ng primer2 0.5 µl 
10mM dNTP 1.0 µl 
Pfu DNA polymerase (2.5 units) 1.0 µl 
H2O up to 50 µl 
 
PCR conditions 
95 °C 30 seconds, then 18 cycles of :  95 °C 30 sec, 55°C 1 min, 68°C  2 min/kb of 
plasmid length. 
After  cooling  down  the  PCR  reaction,  1µl  Dpn  I  (10  unit)  was  added  to  PCR 
reaction and incubated at 37 °C for 1 hr. Then 2 µl of digested PCR reaction were 
added  to  100µl  highly  competent  XL1-Blue  cells  for  normal  transformation. 
Colonies were screened and the mutation was characterized and verified by DNA 
sequencing. 
 
2.2.1.4. DNA sequencing  
 
Plasmid  DNA  and  PCR  products  purified  with  Qiagen  kits  were  used  for 
sequencing reactions. Typical reaction mixtures included: 
Sequencing Mix (Amersham Bioscience) 4µl   38 
Sequencing primers 5 pmol 
DNA template (10 ng DNA for per 100bp in length) 
H2O to 10µl 
 
Sequencing PCR reaction: 
95°C 20 sec 
50°C 15sec 
60°C 60sec 
25 cycles fro PCR product, 35 cycles for plasmid DNA, then holding at 4°C. 
 
Sequencing  reaction  products  were  purified  with  AutoSeqG-50  columns 
(Amersham Bioscience) and processed by MegaBACE sequencer. 
 
2.2.1.5. Polymerase chain reaction 
 
Advantage GC cDNA PCR kit (Clontech) was used for screening recombinant ES 
clones. The user’s manual of the kit was followed for the experiment. Short (20-30 
mers)  oligonucleotide  primers  were  designed  to  have  a  G/C  between  50-60%. 
Standard PCR reactions were performed using the Taq DNA Polymerase with cell 
lysate (template DNA), 1 pmol of each Primer, 0.2 mM dNTP mix and 5ul GC melt 
in 1xPCR buffer. 
 
Standard PCR conditions were as follows: 
First cycle 94 °C, 5 min 
Subsequent 
30 cycles 94 °C, 1 min 
68 °C 3 min   39 
Final Cycle 68 °C 10 min 
 
Genotyping of mice and other normal PCR in this thesis work were performed using 
the Taq DNA Polymerase (Invitrogen), with 5 µl of template DNA (50-100 ng), 1 
pmol  of  each  primer,  1.5  mM  MgCl2,  0.2  mM  dNTP  mix  and  1  u  Taq  DNA 
Polymerase in 1x PCR Buffer, using the following conditions: 
First cycle 95 °C, 5 min 
Subsequent 
35 cycles 95 °C, 1 min 
60 °C, 1 min 
72°C 2 min 
Final Cycle 72 °C 10 min 
All reactions were performed in a Gene Amp PCR System 9600 (Perkin Elmer). 
 
2.2.1.6. Enzymatic treatment of DNA 
 
Cleavage of plasmid DNA: Approximate 2-6 µg of DNA was incubated in 30 µl of 
the  appropriate  buffer  with  5  to  10  U  restriction  enzyme  for  1  to  2  h  at  an 
appropriate  temperature.  Digestion  of  genomic  DNA  was  performed  with  a  final 
concentration of restriction enzyme of 10 u/µg DNA.  
Dephosphorylation  of  DNA  fragments:  For  the  dephosphorylation  of  DNA 
fragments, 10 x buffer, H2O and 1 U (1 µl) of calf intestine alcaline phosphatase 
(CIP) were directly added to the restriction enzyme reaction, incubated for 30 min 
at  37°C  and  heat-inactivated  at  75°C  for  15  min.  Subsequently  the 
dephosphorylated DNA fragments were purified from the reaction mix. Ligation of 
DNA fragments: A 20 µl reaction containing purified linearized vector (approximate 
0.1 µg) and DNA fragments (“insert”) in an 1:3 ratio, 1 µl of T4 DNA ligase (NEB), 
ligation buffer (10 x T4 DNA ligase buffer, NEB) were  incubated overnight at 16°C. 
The reaction was then used to transform competent bacterial cells.   40 
 
2.2.1.7. Random-labelling of DNA probe 
 
DNA probes were radioactively labeled with α-[P
32]-dCTP using the Prime-a- Gene- 
labeling System kit (Promega). 50  ng of  DNA template diluted in 45 µl of dH2O 
were denaturated and labeled by following the kit’s instructions. After adding 5 µl of 
α-[P
32]-dCTP, the reaction was incubated for 60 min at 37 °C.  
 
2.2.1.8. Southern blot analysis of genomic DNA 
 
10 µg of genomic DNA were fully cut overnight with restriction enzyme in a final 
volume of 50 µl. The samples were separated on 0.8% 1xTAE agarose gel at 1,5 
V/cm for 7 h.  The gel was treated sequentialy with denaturation solution (NaCl, 1.5 
M, NaOH 0.5 M) and neutralisation solution (NaCl 1.5 M, Tris/HCl 1 M,  pH 7.4)  
and  then  transferred  overnight  on  a  Nylon  membrane  (Hybond  N
+,  Amersham 
Pharmacia Biotech) in 20 x SSC. After transfer, the membrane was rinsed in 6 x 
SSC,  DNA  was crosslinked to the  membrane by UV irradiation (Stratagene,  UV 
crosslinker) and stored at room temperature. 
Hybridization  reactions  were  performed  with  QuikHyb  Hybridization  Solution 
(Stratagene)  in  an  oven  equilibrated  to  the  appropriate  temperature.  The  pre-
hybridization and hybridization procedures were done following the user’s manual 
from Stratagene. Blots were exposed at –70 °C using Kodak Biomax MR films with 
intensifying screens. 
 
2.2.1.9. Northern blot analysis 
 
A 1% agarose gel was prepared in DEPC treated water. After cooling for about 10 
min, MOPS were added to 1x and 0.6% formaldehyde was added in a fume hood.   
30 µg of total RNA was mixed with sample buffer and incubated at 65°C for 5 min, 
then 1 µl of 1 mg/ml ethidium bromide was added, and samples were loaded on   41 
gel. Electrophoresis in 1x MOPS buffer was performed for about 2-3 h. The gel was 
soaked in 200 ml RNase-free water for 10-15 min and then for 15 min in 50 mM 
NaOH-1.5M NaCl, then the gel was neutralized by soaking in 0.5M Tris-HCl (pH 
7.4)-1.5 M NaCl for 30 min. RNA was transferred overnight to a nylon membrane 
(pre-soaked in 1x MOPS buffer) with a 20x SSC. After transfer, the membrane was 
rinsed in 6x DEPC-treated SSC and then treated by UV crosslinker (Stratagene) for 
2 minutes. Labeling of the probes and hybridization procedures were performed as 
for Southern blot analysis. 
 
2.2.1.10. Preparation of competent bacteria for electroporation 
 
20 ml LB-medium were incubated overnight at 37 °C with a single colony of XL1-
Blue cells. 10 ml of the cultures were then transferred to 400 ml of pre-warmed LB-
Medium and incubated at 37 °C with shaking, until the OD600 reached 0.5. Bacteria 
were harvested by centrifugation (6000 rpm, 20 min) and from here, all the steps 
were performed on ice using prechilled solutions and glassware. The cell pellet was 
subjected to three successive washes by resuspension in ddH2O. Subsequently, 
the pellet was washed once with 10% (v/v) glycerol, and finally resuspended in 5 ml 
of 10% glycerol. 100 µl aliquots of the bacteria were frozen in liquid nitrogen and 
stored at –70 °C. 
 
2.2.1.11. Electroporation of Competent Bacterial Cells 
 
Competent bacterial cells were thawed on ice, 2 µl of ligation reaction were added 
and  the  samples  were  transferred  to  a  prechilled  electroporation  cuvette  (2mm 
electroporation  cuvette,  Eurogentech).  The  cuvette  was  then  placed  in  the 
electroporation  chamber  (Biorad  Gene  Pulser)  and  electroporated  using  the 
following settings: 25  µF, 2.5 kV, 200  Ohm.  Then the bacteria  were transferred 
immediately  to  1  ml  of  LB-medium  and  incubated  at  37  °C  for  1  h.  Cells  were 
pelleted  and  plated  on  LB-agar  plates  containing  the  appropriate  antibiotic,  and 
incubated overnight at 37 °C.   42 
 
2.2.1.12. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Separation  of  proteins  was  carried  out  by  SDS-PAGE.  Protein  samples  were 
treated with SDS-sample Buffer before loading onto the gel; 8 µl of See Blue Plus2 
marker (Invitrogen) were used as molecules weight standard. The gel was run in 
Running Buffer at 20  mA until the  blue dye had reached the bottom of the  gel. 
Thereafter,  the  gel  was  stained  with  Coomassie  blue  or  transferred  to  a 
nitrocellulose membrane. 
 
2.2.1.13. Western blot and Immunodetection of proteins 
 
Proteins were transferred to nitrocellulose membranes (Schleicher & Schull) for 2 h 
at 100 V. After transfer, the membrane was stained for 5 min in Poinceau Solution 
to  visualize  the  transferred  protein  bands.  The  membrane  was  incubated  for  at 
least  1h  in  blocking  buffer  (PBS  containing  5%  nonfat  dry  milk)  at  room 
temperature, rinsed in PBS/ 0.02% (v/v) Tween-20 and incubated overnight at 4 °C 
with  the  primary  antibody  diluted  in  blocking  buffer.  After  5  washes  with 
1xPBS/0.02% (v/v) Tween-20 for 5 min each, the membrane was incubated with 
the secondary antibody diluted in blocking buffer for 1 h at room temperature. The 
blot was washed 4 times in 1xPBS/0.02% Tween-20 and horseradish peroxidase 
(HRP) coupled secondary antibodies were directly detected using the SuperSignal 
West Pico Chemiluminescent Substrate kit (Pierce, USA). Blots were exposed for 1 
s to 20 min using Kodak Biomax MR films. 
 
2.2.1.14. Co-immunoprecipitation 
 
Mouse brains dissected from wild type and homozygous mice were homogenized 
in the Co-IP buffer (50 mM Tris-Cl, pH7.5, 15 mM EGTA, 100 mM NaCl, 1 mM 
dithiothreitol (DTT) plus complete protease inhibitor cocktail (Roche diagnostics)). 
The  homogenate  was  centrifuged  at  800  x  g  for  10  min;  the  supernant  was   43 
collected  and  centrifuged  at  20,000  x  g  for  1  h.  The  resulting  pellet  was 
resuspended in the same Co-IP buffer containing 1% (v/v) Triton X-100, then the 
membranes were solubilized overnight at 4 °C on a shaker. Insoluble material was 
removed by centifugation, and the supernatant was stored at –80 °C after the total 
protein conncentration was determined. For co-immunoprecipitation, the samples 
from wild-type mice were diluted to adjust mGluR7a concentration. The samples 
were  precleared  for  1  h  at  4  °C  with  protein  G–Sepharose  beads  (Amersham 
Bioscience). IP reacton was performed overnight at 4 °C by using 4 ug anti-PICK1 
(N18) (Santa  Cruz Biotechnology)  antibody, followed  by adsorption to  protein  G 
beads.    In  control  experiments,  non-specific  goat  IgG  were  used  instead  of  the 
specific antibodies. After washing the beads, bound proteins were eluted with SDS-
sample buffer and separated by SDS-PAGE and analized by Western blotting. 
 
2.2.2. Cell biology methods 
 
2.2.2.1. Culture of embryonic stem cells (ES-cells) 
 
ES-cells were routinely grown on a monolayer of mouse embryonic fibroblasts at 
37°C. Only low passages of ES-cells were used (less than 15 passages), since 
longer  culture  times  adversely  affect  ES-cell  totipotency.  Cells  were  kept  at  a 
relatively high density and the medium was changed every 24 hours. Cells were 
passaged when plates reached 50% confluency. The plate was washed twice with 
ES-PBS, incubated with ES-Trypsin for 2 min at 37 °C in a 5% CO2 atmosphere 
and cell  aggregates  were disrupted by pipetting  with  a  P200  Gilson  pipette five 
times and subsequent incubation for 1 min at 37 °C. Trypsinization was stopped by 
dilution  with  ES-medium  (1:4),  the  cell  suspension  was  transferred  to  a  15  ml 
Falcon tube and ES-medium were added to a final volume of 10 ml. The cells were 
pelleted for 5 min at 200 g at room temperature, resuspended in ES-medium and 
plated on ME monolayers. 
 
2.2.2.2. Preparation of mouse embryonic fibroblasts (MEFs)   44 
 
Pregnant  female  mice  were  sacrificed  at  E13-E14  by  cervical  dislocation.  The 
embryos were removed from the uterus, and after cutting away the brain and dark 
red organs, washed with fresh PBS in order to remove as much blood as possible. 
The remaining tissue was minced with two scalpels, cells/tissue were suspended in 
several ml of trypsin-EDTA (about 1-2ml per embryo) and incubated under gentle 
shaking  at  37°C for 20  min.   The suspension  was transferred to a  Falcon tube 
containing a suitable volume of DMEM/10% (v/v) FCS and subjected to low speed 
centrifugation  (5  min),  the  resulting  cell  pellet  was  resuspended  in  warm  MEF 
medium and plated out at 1 embryo equivalent per 10 cm dish. The medium was 
changed on the following day, with the fibroblasts being the only cells that attached 
to the dishes.  Plates  were confluent  within one  to a few days.  When the  MEFs 
formed a confluent monolayer, they were trypsinized and replated in T-125 flasks. 
When the flasks were confluent, cells were trypsinized and either frozen in MEF-
freezing  medium  (3x  1  ml  aliquots  per  confluent  T-125)  or  replated  in  3xT-125 
flasks. After the cells had reached confluency, the flasks were trypsinized, and the 
MEFs were pooled in 50 ml of MEF-medium and treated with 6000 rads of gamma 
irradiation to inhibit cell growth and division. The inactivated MEFs were then frozen 
in MEF-freezing medium (3x1 ml aliquots per confluent T-125 flask). 
 
2.2.2.3. Freezing of cells 
 
After trypsinization, ES cells or  MEFs  were pelleted for 5  min at 800 g at room 
temperature  and  resuspended  in  the  appropriate  volume  of  prechilled  freezing 
medim (3 ml of MEF-freezing medium for one confluent T-125 flask; 1 ml of ES-
freezing medim for one confluent well of a 6-well plate). The cell suspension was 
transferred to prechilled 1 ml cryovials and stored for 2 days to 2 weeks at –70 °C. 
For long-term storage, the cells were transferred to liquid nitrogen tanks. 
 
2.2.2.4. Electroporation of the targeting vector into ES cells 
   45 
Plasmid DNA of the targeting vector was prepared according to the Plasmid Maxi 
kit (Qiagen) manual, and the DNA was linearized by Not I digestion. After digestion, 
the targeting vector DNA was precipitated with Na-acetate/ethanol, washed twice 
with 70% (v/v) ethanol, and the DNA was dissolved in TE buffer for electroporation. 
ES-cells from a confluent T-75 flask were trypsinized and cells pelleted for 5 min at 
800 g, at room temperature. The cell pellet was suspended in 800 µl of PBS and 
transferred into 0.4 cm electroporation cuvette  (Biorad). 15 µg of linearized DNA 
were added to the cell suspension and incubated for 5 min at room temperature. 
The cuvette was then placed in the electroporation chamber (Biorad Gene Pulser) 
and electroporated using the following settings: 500 µF, 240 V, τ = 5.7 ms. The 
cells were allowed to recover for 5 min at room temperature, transferred to 100 ml 
of  prewarmed  ES-medium,  and  then  mixed,  distributed  into  10  cm  dishes  with 
feeder  cells.  After  24  h,  the  ES  medium  was  replaced  by  selection  medium 
containing  neomycin  and  FIAU  (5-iodo-2’-fluoro-2’-deoxy-1-Ќ-D-arabino-
furanoside).  ES  cells  were  allowed  to  growth  in  the  selection  medium  with 
neomycin and FIAU for 5-7 days. 
 
2.2.2.5. Selection of ES cell clones 
 
One  day  before  isolating  ES-cell  colonies,  24-well  plates  with  feeder  cells  were 
prepared. The plates with transfected ES-cells were washed twice with PBS, and 
the  cells  were  left  in  the  second  PBS  wash  during  picking.  All  visible  ES  cell 
colonies to be picked were marked on the bottom of each plate with a marker pen 
by holding plate up to light. A P200 pipette set to 8 µl and 1-200 µl filter tips were 
used to pick individule colonies. First, the colonies were slightly dislodged with the 
pipette tip, then the drug-resistant ES cell clones were picked and transferred to a 
well of a 96-well plate.  After picking 24 clones, 75ul trypsin/EDTA were added to 
each well, 10-20 pipetting cycles were used to generate single cell suspension by 
using a multichannel pipettor, then 75ul ES medium were added to each well and 
mixed. One half of the ES cell suspension were transfered into 24-well feeders and 
the other half were used for PCR screening. The same procedure was repeapted 
untill all clones in good shape had been isolated.   46 
 
2.2.2.6. Preparation of ES cells for blastocyst injection 
 
Three days prior to injecton, the frozen ES cells were thawed in 24- well plates with 
feeder cells, and then the ES cells were expanded from 24-well to 6-well plates. 
The ES cells in 6 well with small compact colonies that were in log phase of growth 
were  selected,  the  medium  was  removed  and  ES  cells  were  washed  with  PBS 
twice; trypsin/EDTA were added and incubated at 37 °C for 2 min, then medium 
was added and ES cell aggregates were disrupted by pipetting 10 times. The cells 
suspension were transfered into 2 fresh 6 –well and incubated at 37 °C for 45 min 
(feeders sediment).  The supernatant (fraction1)  was carefully collected, then the 
ES  cells  in  6  well  were  rinsed  with  1ml  medium,  and  the  cell  suspension  were 
carefully transferred to new Eppendorf tube (fraction2), the well was rinsed again 
with another 1ml medium and the ES cells suspension (fraction3) was collected. 
The ES cells from all the three fractions were pelleted and resuspended in 100 ul 
injection medium (ES medium +LIF+20mM HEPES). ES cells from fractoin 2 were 
used for blastocyst injecton, ES cells from fraction1 and 3 were saved for backup. 
 
2.2.2.7. Production of chimeric mice 
 
Recombinant  ES  cell  clones  were  microinjected  into  3.5-day  old  blastocysts 
obtained  from  C57BL/6  female  mice  by  the  Heidelberg  University  Transgenic 
Facility. The microinjected blastocysts were transplanted to pseudo-pregnant foster 
females. Pups were born 17.5 days later. The coat color of pups was examined 6-
10 days after birth for patches of agouti fur.  Each male chimera was rotated with 
two C57BL/6 female mice every 1-2 weeks when they were sexually mature (6-8 
weeks old). One pregnant female mouse was housed per cage. Pups were weaned 
at 21-day old and separated from their mother. 
 
2.2.3.  Immunocytochemistry,  imunohistochemistry  and  immunoelectron 
microscopy methods   47 
 
2.2.3.1. Primary culture of hippocampal neurons for immunocytochemistry 
 
Hippocampal  neurons  were  isolated  from  mouse  E17  embryos.  Embryos  were 
taken out of the uterus and kept in ice-cold PBS, 10 mM glucose buffer. Embryo 
heads were cut off and the scull opened to take out the brain. The hippocampus 
was separated from the cortex. Hippocampi were incubated in papain solution for 
15 min at 37 °C. After digestion, the tissue was washed 2 times in plating medium 
(10%  (v/v)  FCS,  DMEM).  Cells  were  dissociated  by  trituration  with  pipettes  for 
several times. The cell suspension was centrifuged for 5 min at 800 rpm, then  the 
cell pellet was resuspended in Neurobasal medium supplemented with B27. Cells 
were plated onto glass-coverslips precoated with 1.5 µg/ml poly-ornithine. 40,000 
cells /well were plated and incubated for 3-4 weeks at 37 °C. Every week, 1/3 of the 
culture medium was replaced by fresh medium. 
 
2.2.3.2. Immuno-staining and confocal microscopy 
 
For immunocytochemistry, neurons grown on coverslips were fixed with 4% PFA, 
4%  sucrose  in  PBS  for  15  min  at  R/T,  washed  3  times  with  PBS,  then 
permeabilized  for  15  min  with  ice-cold  0.1%  (v/v)  TX-100  in  PBS  at  4°C.  After 
washing, coverslips were blocked for about 30 min at R/T or overnight at 4°C with 
2% (w/v) bovine albumin and 5% (w/v) normal goat serum in PBS. After blocking, 
coverslips were transferred into a dark moist chamber and incubated with primary 
antibodies for at least 8 h at 4 °C. After three washing steps with PBS for 30 min, 
secondary  antibodies,  previously  diluted  in  blocking  solution,  were  added  to  the 
coverslips for 45 min at R/T in the dark. After washing, the samples were mounted 
in Mount media and dried at R/T. Images were acquired using a Leica TCS-SP 
confocal laser-scanning microscope equipped with 40x and 63x objectives. 
 
2.2.3.3. Preembedding immunoelectron microscopy 
   48 
Knock-in  mice  and  wild-type  (8-weeks-old)  littermates  were  deeply  anesthetized 
and  sacrificed  by  cervical  dislocation.  Hippocampi  were  dissected  out  from  the 
mouse  brains  and  immediately  immersion-fixed  in  a  fixative  containing  4%  (v/v) 
paraformaldehyde,  0.05%  (v/v)  glutaraldehyde,  and  0.75%  (w/v)  picric  acid  in 
phosphate  buffer  (PB,  0.1  M,  pH  7.6)  for  2  h,  After  washing  with  PBS,  the 
hippocampi  were  embedded  in  agar  and  sectioned  on  a  vibratome  into  60  µm 
section. Then the vibratome sections were cryoprotected in 10%, 20%, 30% (w/v) 
sucrose for 1 h each, and frozen and thawed twice in liquid nitrogen to increase the 
penetration  of  immunoreagents,  For  preembedding  immunoelectron  microscopy, 
the sections were blocked for 2 h in 10% (v/v) normal goat serum, 1% (w/v) BSA in 
PBS and then incubated with mGluR7a antibody(1:200, 1:400 and 1:1000 dilution 
in 2% NGS,1% BSA, 0.05% Na-azide in PBS.) for 3 days at 4 °C. After washing 
with PBS, the sections were incubated for 2 h with biotinlated goat anti-rabbit IgG 
(1:100, Vector Labs). After rinsing with PBS, section were transfered to a solution 
containing  avidin-biotinylated  peroxidase  complex  (ABC,  diluted  1:100  in  TBS, 
Vector Labs) fro 1 h at room temperature. After washing twice with PBS and twice 
with  0,05  M  Tris-HCl,  pH  7.4,  Peroxidase  was  visualized  with  0.05%  (v/v)  DAB 
using 0.01 % H2O2 as substrate for 8 min. The staining reaction was stopped by 
washing the sections in  Tris-HCl  and PBS.  The sections  were then postfixed in 
2.5% (v/v) glutaraldehyde in cacodylate buffer, pH 7.4 (2 h at 4 °C), and washed 
with double-distilled water, followed by silver intensification to provide particulate 
appearance of peroxidase products (Sassoe-Pognetto et al., 1994). After washing, 
the sections were treated with 0.5% OsO4 in cacodylate buffer for 30 min, washed 
in PBS and contrasted in 2% uranyl-acetate for 2 h. After dehydration in ethanol, 
they  were  embedded  in  Epon  resin  (Fluka,  Taufkirchen,  Germany).  After 
polymerization of the resin, serial ultrathin section were cut and stained with uranyl 
acetate  and  lead  citrate.  Two  brains  of  each  genotype  were  used  for  sample 
preparation,  and  three  blocks  from  each  mouse  were  cut  for  immunoelectron 
microscopy. 
 
2.2.3.4. Immunohistochemistry 
 
Adult mice were sacrificed, and their brains were dissected out and frozen on dry   49 
ice. The cryostat sections were immediately prepared at thickness of 15 µm. The 
sections were fixed in 4% (w/v) PFA/4% (w/v) sucrose for 30 min, then washed with 
PBS  twice.  Sections  were  permeabilized  for  20  min  with  4%  goat  serum/0.5% 
Triton X-100 in PBS, then blocked with PBS/10 %  (w/v) goat normal serum for 3 h 
at R/T. Sections were incubated overnight at 4 °C with the primary antibody. After 
rinsing the sections with PBS, they were incubated 2 h with the secondary antibody 
coupled to a fluorescent chromophore (ALEXA Fluor 488 (green)). Thereafter the 
incubation steps  after the addition of the secondary  antibody  were performed in 
dark. After rinsing in PBS, the slides were coverslipped and imaged. The specifity 
of  labelling  in  all  staining  reactions  was  confirmed  by  the  absence  of  mGluR7a 
labeling upon omission of the primary antibody. 
 
2.2.3.5. NISSL Staining of cryostat sections  
 
Cryostat  sections  were  fixed  in  4%    (w/v)  PFA  and  washed  in  PBS,  and  then 
stained for 5-8 min in cresyl violet (0.5%  (w/v) in 70mM Na-acetate buffer, pH 3.9). 
The dye was rinsed off with demineralised water and the sections were incubated 
for 0.5-1 min in 70% ethanol. The sections were destained under the microscope 
with 90% ethanol with 1-2 drops glacial acetic acid until the brain tissue but not the 
nuclei were destained. After dehydration with 100% ethanol for 1 min then for 2 min 
with 100% Isopropanol, the sections were placed under a hood and incubated in 
Xylol for 2 min and covered with Permount (caution: no air bubbles). For drying, the 
sections were left under the hood overnight until all Xylol had evaporated. 
 
2.2.4. Electrophysiology methods 
 
2.2.4.1. Cerebellar granule cell culture and electrophysiological recordings 
 
Primary cultures of cerebellar neurons were prepared from wild-type or mGluR7a
 
knock-in  mice,  as  previously  described  (Bertaso  et  al.,  2006).  Briefly,  8  day-old 
mice were decapitated, and the cerebella dissected and mechanically dissociated   50 
in  DMEM:F12  medium  (1:1,  Gibco)  supplemented  with  30  mM  glucose,  2  mM 
glutamine, 13 mM sodium bicarbonate, 5 mM HEPES, pH 7.4, 10% semi-synthetic 
calf  serum  (Biowhittaker,  Verviers,  Belgium),  antibiotics  and  KCl  (25  mM).  Cells 
were then plated at a density of 3-5 x 10
5 cells/dish on 35 mm dishes coated with 
poly-L-ornithine.  Half  volume  of  Petri  dish  was  replaced  by  culture  medium 
containing 5 mM KCl 48 hours before electrophysiological recordings.  
Cultured cerebellar granule neurons were used at 9-10 DIV, for whole-cell recordings 
in  the  patch-clamp  mode,  at  room  temperature.  The  recording  pipettes  had  a 
resistance of 3-5 MW when filled with the following medium: 140 mM KCl, 10 mM 
Hepes, 10 mM D-glucose, pH 7.2, osmolarity 300 mosm. Cerebellar neurons were 
continuously  perfused  with  the  following  external  medium:  140  mM  NaCl,  2  mM 
CaCl2, 3 mM KCl, 10 mM Hepes, 10 mM D-glucose, 10 µM glycine, 10 µM bicucullin, 
pH 7.4; osmolarity 330  mosm.  The  membrane  potential  was  held  at - 65mV and 
spontaneous EPSCs (sEPSCs) were recorded through an Axopatch 200B amplifier 
(Axon Instruments; Union City, CA, USA). Currents were filtered at 1 KHz, digitized 
at 3 KHz and continuously stored on a PC computer using the pClamp v.8 software 
of  Axon  Instruments.  Data  were  then  analyzed  using  the  Clampfit  routine  of  this 
software.  Once  a  minimal sample  of at least 120 events  had  been collected, the 
average  frequency  and  amplitude  of  these  events  were  measured  on  the  total 
duration of the sample. L-AP4 was applied using a fast gravity perfusion system that 
allowed complete exchange of the cell environment in less than 50 ms.  
 
2.2.4.2. Surgery and EEG recording 
 
Mice were anaesthetized with 2 ml.kg
-1 of a saline solution containing 40% ketamin 
(Imalgene 500) and 20% Xylazine (Rompun 2%) and placed in a stereotaxic frame 
using the David Kopf mouse adaptor. Five monopolar electrodes made of silver wires 
(d: 125µm, Phymep, France) soldered on a male microconnector (Mateleco, France) 
were extradurally inserted in the skull, 2 on each parietal bone and one on the frontal 
bone as ground reference. The microconnector was fixed with dental acrylic cement. 
After surgery, animals were individually housed and maintained in a 12-h light/12-h 
dark cycle with food and water ad libitum. For the EEG recording, animals were put 
into individual Plexiglas boxes and their microconnectors were plugged to an EEG 
preamplifier box. The electrical activity recorded by deep and extradural electrodes   51 
was  filtered  and  recorded  by  a  computer  equipped  with  Dasylab  software 
(Dasylab®). The EEG recording period was ≥ 80 min and performed in parallel with 
observation of the animal behaviour. 
 
2.2.5.  Animal behavioral assay methods 
 
2.2.5.1. Open field test 
 
The behavior of  mGluR7 knock-in  mice and  wild-type littermates (n = 8 of each 
genotype) in the open field was examined using a brightly lit arena (50 cm º 50 cm 
º 50 cm, 200 lux). Mice were adapted to the test environment for 20 min and then 
placed in the center of the arena for 5 min.  Movements of the mice in the arena 
were recorded using the VIDEOMOT video tracking system (TSE-Systems,  Bad 
Homburg,  Germany).  Locomotor  activity  was  monitored  by  measuring  the  total 
distance and speed of the animals during the test. The ratio of the distance traveled 
in  the  center  vs.  the  periphery  of  the  arena  were  evaluated  as  a  measure  of 
anxiety. 
 
2.2.5.2. Elevated plus-maze test 
 
The elevated plus-maze was used to further assess anxiety and the exploratory 
behavior of the mGluR7 knock-in mice (n = 12 per genotype). The arena consisted 
of a plus-shaped maze with two arms of 25cm that were closed by high side walls 
and two open arms without walls. The maze was located 40 cm above the table 
surface.  Mice  were  placed  on  the  open  arm  of  the  maze  and  were  allowed  to 
explore the maze freely for 10 min. Movements were analyzed using VIDEOMOT 
video  tracking  system  (TSE-Systems,  Bad  Homburg,  Germany).  Mice  were 
considered to be in the open region when all four paws were located on the open 
portion of the maze. The time spent in the open arms was used as a measure of 
anxiety.   52 
 
2.2.5.3. Tail flick test  
 
Pain sensitivity to acute thermal stimuli was assessed by tail flick test.  The animal 
was gently constrained and the tip of its tail was placed above an infra-red heat 
source (TSE-Systems, Bad Homburg, Germany) that applied a heat stimulus with 
linear increasing intensity to the tail. The time taken by the animal to flick its tail was 
recorded.  For  each  animal,  the  response  was  monitored  three  times  at  distinct 
positions of the tail. 
 
2.2.5.4.  Acoustic startle response and prepulse inhibition 
 
Acoustic startle response and prepulse inhibition of startle were assessed using a 
standard startle chamber (TSE-Systems, Bad Homburg, Germany) and 10 different 
trials: acoustic startle pulse alone (100 dB), prepulse trials with 70-, 80-, 85- or 90-
dB stimuli presented either alone or preceding the pulse, and one trial in which only 
the background noise (60 dB) was presented to measure the baseline movement. 
The amount of PPI in the prepulse plus pulse trials was expressed as a percentage 
of the startle response in the pulse alone trial. 
 
2.2.5.5. Barnes maze task 
 
Twenty males of the mGluR7 knock-in mouse line (mutant and wild type: n = 10 
each)  were  assessed  on  the  spatial  version  of  the  Barnes  maze.  The  Barnes 
circular maze,  a white platform (122 cm in diameter), was elevated 90 cm above 
the floor. Forty holes, 5 cm in diameter each, were located 5 cm from the perimeter, 
and a black plastic escape tunnel was placed under each of the holes, which was 
conected to the home cage of the animal. One training trial was performed before 
the first day of testing. To this end, the mouse was placed in the center of the maze 
and covered with a 15 cm high black start chamber for 2 min. Immediately after 
removing the start chamber,  mouse  was guided by the  investigator to  enter the   53 
escape tunnel and then to the cage. One min after this training trial, the first test 
session started. At the beginning of each session, the mouse was placed in the 
center of the maze in the black start chamber for 2 min. After removing the start 
chamber, the mouse was allowed to explore and escape the maze. The session 
ended when the mouse entered the escape tunnel or if not successful, the mouse 
was guided after 5 min to enter the escape tunnel. When the mouse entered the 
escape tunnel, the mouse was allowed to reach the home cage and the trial was 
ended for this day. During each trial, the tunnel was always located underneath the 
same hole, which was randomly determined for each mouse. The mice were tested 
once every day until they met the defined criterion (4 out of 5 sessions with two or 
fewer errors). The testing ended after 32 sessions. The search strategies (serial 
random and spatial ) were defined as described elsewhere (Bach et al., 1995) .   
 
3. Results 
 
3.1. Generation of mGluR7a knock-in mice 
 
The  development  of  gene  targeting  technology  (Thomas  and  Capecchi,  1987; 
Melton, 1994) has made it possible to produce genetically modified mouse models 
for determining  gene functions in the  brain.  Gene targeting approaches  and the 
application of site-specific recombinase technology provide investigators with the 
opportunity to engineer genes in the mouse that will allow for the deletion, insertion, 
inversion,  or  exchange  of  chromosomal  DNA  with  high  fidelity  (Branda  and 
Dymecki,  2004).  The  ability  to  modify  expression  of  specific  genes  in  mice  has 
revolutionized the field of molecular neuroscience. There are two principal types of 
mouse models that can be created, knock-out and knock-in mice. Knock-out mice 
carry a gene mutation introduced into the genome by a natural biological process 
called  homologous  recombination,  in  which  the  endogenous  gene  in  mouse 
embryonic stem (ES) cells gene is replaced by DNA that disrupts gene function. 
The targeted ES cells will be used to produce chimeras and further knock-out mice. 
Using the same method, knock-in mice are generated to contain a specific mutation 
(deletion, substitution etc.) within the targeted gene that results in a protein with   54 
altered gene function. For both knock-out and knock-in, a targeting vector has to be 
assembled  that  contains  sequences  of  genomic  DNA  homologous  to  the 
chromosomal integration site, the mutant gene or exons, the selection cassettes for 
positive and/or negative selection, and a plasmid backbone. In this work presented, 
the ‘‘Replacement –type ’’ targeting vector was used to generate the knock-in mice 
which carry the specific mutation at the genomic locus of metabotropic glutamate 
receptor 7a (mGluR7a). 
To generate mGluR7a knock-in mice, a mutation has to be correctly introduced into 
the mouse mGluR7 genomic locus; therefore the genomic orgnization of mGluR7 
must be known and genomic clones must be obtained for constructing the targeting 
vector.  The  rapid  progress  of  the  Mouse  Genome  project  has  provided  ample 
genome sequencing information, and many genomic BAC clones are commercialy 
available. The mouse mGluR7a gene details can be found at the following website:  
http://www.ncbi.nlm.nih.gov/genome/guide/mouse.  Briefly,  the  gene  is  located  on 
mouse  chromosome  6  near  the  region  Chr6:110611375-111533007  bp,  and  the 
gene’s ID at Mouse Genome Informatics is MGI:1351344.  
In  order  to  identify  BAC  clones  suitable  for  constructing  a  targeting  vector,  the 
mouse mGluR7a cDNA sequence was used to blast and search mouse genomic 
sequence database:  
http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090.  
Among all clones screened, one particular BAC clone RP23-391F16 was selected 
because  it  contained  exon10  and  its  surrounding  region.  Exon10  encodes  the 
PICK1  binding  domain  in  the  C-terminal  region  of  mGluR7a,  and  the  mutation 
disrupting the PICK1-mGluR7a interaction was introduced precisely into exon10.  
The  BAC  clone  RP23-391F16  was  ordered  from  BACPAC  resources  center, 
children’s  hospital  oakland  and  its  sequence  can  be  found  in  the  database.  To 
confirm that this BAC clone contained sufficient genomic sequence for targeting 
vector  construction,  an  initial  PCR  analysis  was  performed,  which  showed  that 
exon10 and its surrounding sequence were intact within the BAC clone (data not 
shown). Based on the sequence of clone RP23-391F16 available in the database, 
the exon10 containing genomic fragment spanning 9.8 kb of  genomic sequence 
was  subcloned  into  pBluescript-SK  by  Bgl  II  digestion.  This  9.8  kb  genomic   55 
sequence was further characterized by restriction mapping and sequencing (Figure 
5) and used for the construction of the targeting vector. 
 
 
Figure 5. Restriction map of the exon10 containing 9.8 kb genomic fragment used for 
targeting vector construction.  Several restriction sites are  indicated, and  the grey bar 
represents exon10 which encodes the PICK1 binding motif. 
 
3.1.1. Gene targeting strategy 
 
The mGluR7a-PICK1 interaction site has been mapped and the last three amino 
acids (-leucine-valine-isoleucine) of the C-terminal region of mGluR7a are crucial 
for the interaction with PDZ domain of PICK1(El Far et al., 2000). Substitution or 
deletion  of  last  three  amino  acids  abolished  the  mGluR7a-PICK1  interaction 
(Boudin  et  al.,  2000).  Based  on  this,  the  strategy  of  the  gene  targeting  was 
designed to  mutate the PICK1 binding  motif (-LVI) to triple alanine (-AAA). This 
mutation had to be introduced into embryonic stem (ES) cells and then targeted ES 
cells  would  be  used  to  generate  a  knock-in  mouse  in  which  mGluR7a-PICK1 
interaction should be abolished. Because the PICK1 binding motif (-LVI) is located 
in the exon10 of mGluR7 genomic locus, all gene targeting work was based on the 
surounding regions of exon10 as illustrated in Figure 6.  
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Figure  6.  Strategy  for  the  generation  of  mGluR7a  knock-in  mouse.  Homologous 
recombination at the exon10 region of mGluR7 genomic locus. The triple alanine mutation 
was introduced into targeted allele, note the presence of the mutation before and after the 
Cre excion of the Neo cassette. E: EcoRI, B: BamHI, Bg: Bgl II, P: PvuII, H: HindIII, Lox: 
LoxP sequence, Neo: neomycin resistance cassette, TK: Herpes Simplex Virus Thymidine 
kinase cassette. 
 
In this strategy, the gene targeting vector contained a positive selection cassette 
(Neo), a negative selection cassette (TK), and two homology regions (5’ and 3’) 
which were placed upstream and downstream of the positive selection cassette. 
The  neo  cassette  was  removed  at  the  ES  cell  level.  If  successful,  homologous 
recombination should introduce the triple alanine mutation into mGluR7a locus and 
thereby disrupt the  mGluR7a-PICK1 interaction. The functional consequences  of 
the disruption of this interaction can then be studied in detail. 
 
3.1.2. Assembly of gene targeting vector 
 
The plasmid backbone which was used for the construction of the targeting vector 
was pEasyflox. Both the neomycin cassette and the HSV-TK cassette in pEasyflox   57 
serve  as  selection  marker,  but  only  the  neomycin  cassette  is  flanked  by  loxP 
sequences. A flow diagram for constructing the gene targeting vector is illustrated 
in  Figure  7,  the  construct  was  verified  by  DNA  sequencing  before  ES  cells 
transfection. 
 
 
Figure 7. Construction of the gene targeting vector.  In the final construct,  the  target 
mutation  (three  alanine  codons)  was  introduced  by  site-directed  mutagenesis,  the  Neo 
cassette was flanked by two loxP sequences. 
 
Briefly, the targeting vector was constructed in the follwing steps: 
1.  Amplification of the 1.5 kb 5’ short homology region from the initial 9.8 kb 
genomic fragment by PCR and insertion into pEasyflox by BamHI site. 
2.  Isolation of the 1.9 kb fragment containing the PICK1 binding motif by EcoRI 
digestion  of  the  initial  9.8  kb  genomic  fragment  followed  by  subcloning  into 
pBluescript-SK, and then replacement of the last three amino acids codons (LVI) by 
three  alanine  codons  via  site-directed  mutagenesis  (Stratagene  Quickchange 
Mutagenesis Kit). See Figure 8 for the design of the target mutation.   58 
3.  Further  subcloning  3.2  kb  fragment  (right  after  the  1.9  kb  fragment)  by 
EcoRI  +  SmaI  digestion  of  the  initial  9.8  kb  genomic  fragment  and  ligated  to 
pBluescript-SK (cut with EcoRI/EcoRV). 
4.  Isolation of  the mutant 1.9 kb fragment (which carry the AAA mutation) by 
EcoRI cutting and ligation to a 3.2 kb fragment at the EcoRI site in pBluescript-SK, 
resulting in the 5.1 kb 3’ long homology region. 
5.  Isolation of the 5.1 kb long homology region (with mutation) by cuting with 
XbaI and XhoI and ligated to XbaI and XhoI restriction site in  pEasyflox + short 
homology region. 
The final construct could be linearized by Not I for gene targeting in ES cells. 
 
 
 
Figure  8.  Introduction  of  the  triple  alanine  mutation  in  Exon10  of  mGluR7.  The 
mutation was introduced into exon10 of mGluR7 using the mutagenesis primers indicated. 
As a result, in the mutant mGluR7a protein, the last three amino acids were substituted by 
triple alanines. Note that a new restriction site, Pvu II (underlined), occurred naturally after 
introduction of the mutation, which was used in the screening of the ES clones and the 
identification of the knock-in genotype. 
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3.1.3. Electroporation of ES cells and identification of homologous 
recombination events 
 
For the generation of the knock-in mice, the E14 (129/OLA) embryonic cell (ES) 
line was used. This ES cell line can efficiently generate germline chimeras after 
blastocyst  injection  due  to  an  increased  surrival  rate  of  blastocysts  in 
pseudopregnant mothers as compared with other types of ES cells. To maintain the 
ES  cells  in  an  undifferentiated  state,  they  were  cultured  on  the  feeder  layer  of 
inactivated  mouse primary fibroblasts in the presence  of recombinant leukaemia 
inhibitory  factor  (LIF)  in  the  medium.  The  E14  ES  cells  were  electoporated  at 
passage 9 with linearized targeting vector and grown for nine days under double 
selection of G418 and FIAU. When the surviving ES colonies were large enough for 
subcloning and expansion, those with undifferentiated morphology were selected 
for further analysis. In total, 148 clones were picked and trypsinized gently in a 96-
well plate and then ES medium was added for resuspension of the cells. Half of the 
ES cell resuspension was plated on a 24-well feeder plate for clone expansion, the 
other half  was collected and immediately subjected to PCR analysis  in  order to 
screen for correct homologous recombination events. The PCR- positive ES clones 
were expanded on the 24–well plates until confluent, trypsinized and resuspended 
in  ES  medium.  70%  of  the  resulting  cell  suspension  was  frozen  in  the  liquid 
nitrogen by adding  ES cell freezing  medium,  and the remaining 30% of the cell 
resuspension was plated on gelatinized 24-well plates for the preparation of ES cell 
genomic DNA. This genomic DNA was later used for Southern blot analysis. For 
PCR screening of ES clones, primer 7 and 8 (see materials and methods) were 
used for the  amplification  of the target fragment. The  primer  8 binding site  was 
exactly located at the beginning of the neomycin cassette, while primer 7 extended 
to  outside  of  the  short  homology  region,  therefore  the  primer  7/8  combination 
detected only correctly targeted ES clones. Among all the ES clones isolated, 4 
clones  were  identified  to  have  undergone  homologous  recombination  correctly 
(Figure  9).  The  PCR  screening  of  the  homologous  recombination  events  was 
further  confirmed  with  Southern  blot  analysis.  The  Southern  blot  probe  was 
amplified  (primer  9  and  10)  by  using  original  9.8  kb  genomic  fragment  as  PCR 
template.  This  probe  was  located  outside  of  the  genomic  region  present  in  the   60 
targeting vector, and therefore could be used as an external probe. Southern blot 
analysis  of  ES  cell  genomic  DNA  using  BglII  digest  revealed  that  this  probe 
hybridized to a 9.8 kb WT, or a 5.4 kb mutant fragment (Figure 9). Thus, both PCR 
and southern results indicated that homologous recombinaton had occured in the 
targeted ES clones, suggesting that the triple alanine mutation was introduced into 
exon10 of one of the mGluR7 alleles. 
 
 
Figure 9. Identification of homologous recombinaton events by  PCR and southern 
blot  analysis.  A.  Strategy  of  PCR  and  Southern  blot  for  screening  of  homlogous 
recombination events. The specificity of PCR screening was dertermined by the position of 
primer8, and also note the position of 5’ external probe. B. PCR screening of ES clones 
with the combination of primer 7 and 8.  Correct homologous recombination yielded a 1.9 kb 
band which extended over the short homology region. C. Southern blot analysis of Bgl II-
digested ES cell genomic DNA using the 5’-external probe. The wild-type allele gave a 9.8 
kb band and the targeted mutant allele produced a 5.4 kb band. 
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3.1.4. Cre recombinase mediated deletion of the Neo resistance cassette in 
ES cells 
 
It should be pointed out that upon introduction of  the triple alanine mutation into 
exon10  of  mGluR7  locus  (described  in  3.1.1),    the  neomycin  resistance  (Neo) 
cassette was also inserted simultaneously. It is now widely accepted that selection 
marker  cassettes  should  be  removed  after  homologous  recombination  (Muller, 
1999). One reason is that the expression of neomycin cassette is driven by a very 
strong promoter (PGK-neo cassette), which may interfere with the expression of 
neighboring genes. Furthermore, the presence of the neomycin cassette may also 
influence  the  splicing  efficiency  and  stability  of  transcripts.  Hence,  the  mutant 
phenotypes may be due to effects exerted by the selection marker and not caused 
by the mutation itself. Here, removal of the Neo cassette was achieved by using the 
Cre-LoxP system. This system is frequently used for the generation of genetically 
modified  animals.  Cre is  a  38 kDa recombinase protein from  bacteriophage P1, 
which cuts at loxP-tagged sequences (Kuhn and Torres, 2002). 
   62 
Figure 10. PCR and Southern blot analysis of Cre-recombinase mediated deletion of 
neomycin  resistance  cassette.  A.  Strategy  for  PCR  and  Southern  blot  confirmation  of 
removing Neo cassette. B. Representative PCR screening of ES clones after excision of the 
neomycin cassette using the combination of primers 13 and 14. Lane1, molecular marker; 
Lane 2, 3, 4, 6, 7, 8, 9, 10, PCR-positive clones (596 bp band), indicating correct deletion of 
neomycin cassette; Lane 5, 11, 12, 13. PCR-negative clones. C. Pvu II digested genomic 
DNA was hybridized with an internal probe. The wild-type allele gave a 1927 bp band, the 
targeted allele produced a shorter fragment (1827 bp) due to the introduction of an extra 
Pvu II restriction site within the triple alanine mutation. 
 
To remove the neomycin resistance cassette in ES cells, one targeted ES clone 
with correct homologous recombination was selected for expansion and transient 
transfection  with  the  Cre  expression  plasmid  pGK-Cre.  After  transfection  and 
allowing  for  expression  of  Cre  recombinase  in  the  ES  cells,  24  ES  clones  with 
homogenous morphology were picked and screened by PCR and Southern blot. 
This showed that 14 clones had undergone correct Cre-mediated excision of the 
neomycin cassette. For the PCR screening, primers 13 and 14 were used.  Primer 
14 covers a partial region of the LoxP sequence, and if the neomycin cassette was 
removed correctly, the combination of primers 13 and 14 yielded a specific 596 bp 
band (Figure 10B). The PCR screening results were further confirmed by Southern 
blot analysis; here, the Southern probe was amplified by PCR using the primers 11 
and 12, and the initial 9.8kb genomic fragment as template. When hybridized to 
Pvu  II-digested  genomic  DNA,  this  internal  probe  detected  a  1927  bp  wild  type 
band, while the new PvuII restriction site at the triple alanine mutation resulted in 
1826 bp band indicative of the targeted allele (Figure 10C). 
After confirming proper excision of the neomycin cassette, another PCR analysis 
(primer  15  and  16)  was  performed  to  check  whether  the  targeted  triple  alanine 
mutation was detectable after two rounds of selection and screening. Sequencing 
of the PCR products showed that the desired mutation was indeed present (data 
not shown). 
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3.1.5. Production of chimeric mice by blastocyst injection of ES cells 
 
Production of chimeric mice by injecting embryonic stem cells into the cavity of a 
mouse blastocyst is a highly critical step in the generation of mutant mouse models. 
Chimeric mice resulting from the injected blastocysts will be composed of tissue 
derived from the inner cell mass of the host blastocyst as well as from the ES cells. 
It is possible that ES cells contribute to all cells of the chimeric mouse, including the 
germline cells. Commonly, chimeric mice are produced from ES cells derived from 
agouti 129/SV mice and host blastocysts harvested from black C57Bl/6 mice. This 
was also the case here. The injection of ES cells was done by Frank Zimmermann 
from the Centre of Molecular Biology, University Heidelberg. Two correctly targeted 
ES  cell  clones  (mgr10,  mgr14)  were  microinjected  into  blastocysts  derived  from 
C57BL/6  mice.  The  microinjected  blastocysts  were  transplanted  into 
pseudopregnant female mice. For one clone (mgr10), 6-7 cells were injected into 
each blastocyst; in total, 33 blastocysts were injected, and 3 recipient female mice 
were used. For another clone (mgr14), 32 blastocysts were injected (6-7 cells per 
blastocyst)  and  3  pseudopregnant  female  mice  were  also  used  for  blastocyst 
transplantation. The production of chimeras resulting from these microinjection of 
ES cells is summarized in Table 2. 
 
Table 2. Summary of chimeric mice production from ES cell injection 
 
 
 
ES cell clone 
injected 
Offspring born  Pups dying shortly 
after birth 
Chimeras 
generated 
mgr10  13  5  3 
mgr14  20  0  11   64 
The  offspring  was  examined  for  coat  color  when  mice  were  10  days  old.  Mice 
displaying >70% agouti coloring were supposed to likely have ES cell contribution 
to the germline. The  ES cells  used for injection and some of the chimeric  mice 
generated are shown in Figure 11. 
 
 
Figure 11.  Production of  chimeras by blastocyst  injection of ES cells. A. Correctly 
targeted ES cell clones were selected for blastocyst injection; image shows representative 
ES  cells  prior  to  injection.  B.  Chimeric  mice  show  the  agouti  coat  color  (light  brown), 
indicating that chimeras have cells derived from recombinant 129/OLA ES cells. 
 
3.1.6. Germline transmission of the mutation and generation of homozygous 
mutant mice  
 
If  chimeric  mice  carry  germ  cells  derived  from  injected  ES  cells,  Any  targeted 
mutation  introduced  into  the  ES  cells  will  be  transmitted  to  the  offspring.  After 
breeding  of  the  chimeric  mice  with  C57BL/6  mice,  if  germline  transmission  was 
achieved, the offspring will have one allele from the ES cells, and its coat color will 
be all agouti. Non-germline transmitting mice will carry only alleles from C57BL/6 
mice and will be all black. Since only one mGluR7 allele in these targeted ES cells 
was  mutated,  50%  of the agouti pups  are expected to carry the  mutated  allele. 
Figure 12 shows that when the chimeric mice were bred with wild-type C57BL76 
mice, germline transmission of the PICK1 binding domain mutation (triple alanines)   65 
was obtained in F1 generation mice, based on the agouti coat color of the offspring. 
To identify agouti pups carrying the  mutated allele,  F1  mice  were  genotyped by 
PCR  (primer  15  and  16).  For  the  PCR  screeing,  the  3’  end  of  the  reversing 
primer16 was exactly located at the triple alanine mutation, thereby yielding specific 
amplification products (582 bp). These PCR-positive mice should be heterozygous 
for the mutation (mGluR7a
+/AAA). 
 
Figure  12.  Generation  of  F1  mice  with  germline  transmission  of  the  triple  alanine 
mutation. A. Breeding of chimeric mice with C57BL/6 mice resulted in F1 offspring with 
agouti coat color, indicating that germline transmision of the mutation had been obtained. B. 
PCR genotyping of F1 mice with primers 15 and 16.  Lanes 2, 4, 10, 11 12 shows PCR-
positive (582 bp) heterozyous mice Lanes 1, 3, 5, 6, 7, 8, 9 correspond to non-mutant mice 
among the F1 offspring. 
 
The F1 heterozygous mice were then backcrossed to wild-type C57BL/6 mice for 6 
generations to avoid effects of a mixed genetic background (129/OLA/C57BL/6) on 
phenotype  analysis.  The  backcrossed  heterozygous  mice  were  interbred  to 
generate homozygous  mice. Offspring from breeding  heterozygotes  was born  at 
Mendelian ratios, with 25% wild type (+/+), 50% heterozygotes (mGluR7a
+/AAA), and 
25% homozygous mice (mGluR7a 
AAA/AAA). The genotyping of the offsprings was 
performed by PCR (Figure 13A) with the primers 21and 22, and also confirmed by 
Southern blot analysis (Figure 13B).    66 
In order to assess whether mGluR7a 
AAA/AAA mice expressed mGluR7a at normal 
level in the brain, total brain mRNA was prepared from mice brain and hybridized 
with  a  specific  mGluR7a  probe  (generated  with  primers  19  and  20  from  the 
mGluR7a cDNA). β-Actin was used as loading control. The Northern blot shown in 
Figure 13C indicated that the mGluR7a mRNA level in wild-type and KI mice were 
similar. 
 
 
 
Figure 13.  Generation of mGluR7a knock-in homozygous mice (mGluR7a 
AAA/AAA) and 
northern-blot  analysis.    A.  PCR  genotyping  of  offspring  from  heterozygote  breedings 
revealed  3  different  mouse  genotypes.  Lane  1:  molecular  marker,  Lanes  2,  3:  wild-type 
(+/+); Lane 4, 6, 8, 9: heterozygous KI mice (mGluR7a
+/AAA); Lanes 5, 7, 10: homozygous 
KI mice (mGluR7a 
AAA/AAA). B. Confirmation of the genotype by Southern blot analysis. 
The internal probe hybridized to two bands in heterozygous mice (1927 bp and 1836 bp), 
and only one specific band in wild-type and homozygous mice, respectively. C. Northern-
blot analysis showed that there was no alteration in mGluR7a mRNA expression level in the 
KI mice. 
 
In order to check whether the knock-in mice (mGluR7a 
AAA/AAA) indeed express the 
triple  alanine  mutation  designed  to  disrupt  mGluR7a-PICK1  interaction,  the 
intracellular region of the mGluR7a mRNA was amplified by RT-PCR with primer 17 
and 18. Sequencing of the RT-PCR products showed that in homozygous KI mice   67 
the  PICK1 binding  motif (LVI)  was correctly replaced by three  alanine residues, 
while the respective coding sequence was unchanged in the wild-type littermates 
(Figure 14B, C). 
 
Figure 14. Confirmation of PICK1 binding domain mutation in homozygous KI mice. 
A. Amplification of the intracellular domain coding region of mGluR7a mRNA by RT-PCR. 
Note that there is no PCR product in the control experiment without reverse transcription. B. 
Sequencing of RT-PCR products from KI mouse shows successful subsituion of LVI codons 
by AAA codons.  C. Normal mGluR7a sequence in the wild-type littermates. 
 
3.2.  Biochemical,  anatomical  and  electrophysiological  characterization  of 
homozygous KI mice  
 
It is generally thought that mGluR7 is one of the most important mGluR subtypes in 
regulating CNS function (Dev et al., 2001). The first mGluR7-related mutant animal 
model was the mGluR7 knock-out mouse (Sansig et al., 2001b). The analysis of 
this  mouse  model  has  suggested  a  primary  role  of  mGluR7  in  the  negative 
modulation of physiological glutamate release and possibly the etiology of epilepsy. 
In this thesis, a new mutant mouse model was generated, in which the mGluR7a-
PICK1  interaction  was  disrupted.  The  phenotypic  characterization  of  the  mutant 
mice was performed carefully, but it turned out that the homozygous KI mice were   68 
born  viable  and  showed  no  abornalmality  in  size  and  gross  appearence  as 
compared with their wild-type littermates. The mutant mice bred normally and well 
groomed and a Mendelian ratio of inheritance was observed among the offspring 
produced by intercrossing heterozygous animals. 
For  further  biochemical  characterization  of  the  mutant  mice,  mGluR7a  protein 
expression and distribution in the brain were examined. Furthermore, the synaptic 
targeting and clustering of mGluR7a and mGluR7a mediated G-protein dependent 
signaling events were investigated in detail in the homozygous KI mice. 
 
3.2.1. Expression of mGluR7a in homozygous KI mice 
 
 As mentioned above, the Northern blot analysis had revealed that mGluR7a gene 
transcription was not altered in the homozygous KI mice (Figure 13C). However, 
significant difference in mGluR7a expression was found at the protein level. The 
mGluR7a protein was detected by Western blotting in the membrane preparations 
from mouse brain. Quantification of the band intensities indicated that protein levels 
of  mGluR7a in the  homozygous  KI  mice  was  reduced  by 40% and  also slightly 
reduced in heterozygous  mice (Figure  15A, B).  In contrast, expression levels  of 
PICK1, a strong binding partner of mGluR7a, were not different between mutant 
and wild-type littermates, indicating that PICK1 expression was not down-regulated 
by the triple alanine mutation. Since all group III mGluRs (mGluR 4, 6, 7, 8) share 
high sequence identity and similar pharmacological properties, it was interesting to 
learn whether the expression levels of other group III mGluR members was altered 
upon introducing triple alanine mutation. Here, mGluR4 was selected for Western 
blot analysis. No difference was found between KI and wild-type mice (Figure 15 A, 
B).   69 
 
Figure 15. Expression of mGluR7a, mGluR4 and PICK1 in the brain of heterozygous 
and homozygous KI mice.  A. Western blot detection of mGluR7a, mGluR4, and PICK1 in 
brain extracts prepared from wild-type, heterozygous and homozygous littermates, β-tubulin 
was used as control. Protein expression levels were normalized to the internal standard β-
tubulin. B. Quantification of the Western blot results. Note significant reduction of mGluR7a 
expression in homozygous KI mice (P< 0.05, student’s t test), while no difference was found 
for  mGluR4  and  PICK1  expression  between  wild-type  and  KI  animnals.  The  results 
represent  means ± SEM, n=8 mice for each genotype. 
 
3.2.2. Reduced mGluR7a–PICK1 interaction in homozygous KI mice 
 
Previous work has shown that the PICK1 PDZ-domain binding motif is located in 
the  last  three  amino  acids  residues  (LVI)  of  the  mGluR7a  C-terminal  region, 
deletion or substitution of these residue results in abolishment of PICK1binding to 
mGluR7a (El Far et al., 2000). To test whether PICK1 still interacts with mGluR7a 
in homozygous KI mice, a co-immunoprecipitation experiment was performed using 
a  PICK1  antibody.  The  mGluR7a–PICK1  immuno-complex  was  robustly 
precipitated from wild-type brain extracts, while it was strongly reduced in mutant 
mice  (Figure  16  A,  B).  This  indicates  that  the  PICK1–mGluR7a  interaction  is 
efficiently disturbed in the mutant mice.   70 
 
Figure  16.  Co-immunoprecipitation  of  mGluR7a  and  PICK1  from  brain  extracts  of 
wild-type  and  KI  mice.    A.  PICK1  antibody  and  control  IgG  were  used  for  co-
immunoprecipitation, followed by Western blot analysis with the indicated antibodies. Note 
that reduced amount of mGluR7a were pulled down from KI brain extracts. B. Quantification 
of the immuno-blotting results showed  that the  mGluR7a-PICK1 interaction was strongly 
reduced in KI mice. The same experiment was repeated 4 times, and the results are shown 
as means ± SEM. 
 
3.2.3. Homozygous KI mice show normal gross brain anatomy and mGluR7a 
distribution 
 
To examine whether the triple alanine mutation introduced into the mGluR7 locus 
may have effects on mouse brain anatomy, Nissl staining was used to analyze the 
morphology  of  the  brain  in  sagittal  sections,  KI  mice  showed  no  detectable 
abnormalities  in  brain  cytoarchitecture  as  compared  with  the  wild-type  controls 
(Figure  17  A,  C).  Similarly,  immunohistochemical  staining  of  mGluR7a  with  the 
mGluR7a antibody revealed no major difference in general distribution of mGluR7a 
between wild-type and mutant animals (Figure 17 B, D). For both Nissl staining and 
mGluR7a antibody staining, the data were obtained for the whole brain, but for the 
reason of simplicity, only data from representative hippocampus region was shown. 
To  sum  up,  these  results  show  that  the  triple  alanine  mutation  at  the  C-tail  of   71 
mGluR7a  produced  no  detectable  alteration  in  brain  anatomy  and  mGluR7a 
expression pattern. 
 
 
Figure 17. Normal cytoarchitecture and mGluR7a staining in the hippocampus of KI 
mice. (A, C). Nissl staining of sagittal brain sections showed no differences in hippocampus 
anatomy between wild-type and KI mice. (B, D). The distribution of mGluR7a was detected 
by immunohistochemistry. Antibody staining revealed no major differences between wild-
type and KI mice . 
 
3.2.4.  Synaptic  targeting  and  localization  of  mGluR7a  in  homozygous  KI 
neurons 
mGluR7a  has  been  previously  shown  to  localize  presynaptically  in  cultured 
hippocampal neurons (Stowell and Craig, 1999). PICK1 is thought to serve as an 
adaptor protein which organizes presynaptic portions at synaptic contacts (El Far 
and  Betz,  2002).  Boudin  et  al.  (2000)  reported  that  a  mutant  mGluR7a  protein 
which lacks the PICK1 binding domain at its C-terminal region is targeted to the 
axonal membrane efficiently, but not clustered at the axon terminals (Boudin et al., 
2000).  Here,  I  analyzed  the  synaptic  localization  of  mGluR7a  in  hippocampal   72 
neurons  prepared  from  the  homozygous  KI  mice.  Immunofluorescence  labeling 
showed  that  mGluR7a  clustering  was  unchanged  in  mutant  neurons.  They 
displayed the same punctate distribution as wild-type neurons in primary cultures. 
Furthermore,  the  mGluR7a  punctate  staining  colocalized  with  the  presynaptic 
marker synapsin 1 in both wild-type and mutant neurons (Figure 18). These data 
indicate that PICK1 binding to the C-terminal region of mGluR7a is not essential for 
its membrane targeting and synaptic localization. 
 
Figure 18. Immunostaining of mGluR7a in wild-type and KI hippocampal neurons. A. 
Immunofluorescence  labeling  of  mGluR7a  and  the  presynaptic  marker  synapsin  1  in 
cultured  wild-type  hippocampal  neurons.  Note  that  the  mGluR7a  and  synapsin1 
immunoreactivities  colocalize.  B.  The  colocalization  of  mGluR7a  and  synapsin1  is 
unchanged in hippocampal neurons KI mice. Scale bar, 10 µM. White boxes in the upper 
panels (A1-A3, B1-B3) define enlargements shown in the lower panels. 
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3.2.5. Ultrastructural localization of mGluR7a by immunoelectron microscopy 
 
To  finally  examine  the  localization  of  mGluR7a  at  hippocampal  synapses  in 
mGluR7a KI mice ultrastructurally, immunoelectron microscopy experiments were 
performed on hippocampi of 8 week-old mouse using a mGluR7a antibody raised 
against the C-terminal region. The detection of mGluR7a was carried out using a 
highly  sensitive  method  combining  peroxidase  staining  with  silver  intensification 
and gold toning on the CA-3 region of mouse hippocampus. Consistent with other 
published  data  (Shigemoto  et  al.,  1996;  Dalezios  et  al.,  2002),  the  mGluR7a 
immunoreactivity in the CA-3 region of wild-type animals was mostly concentrated 
along the presynaptic active zone in nerve terminals (Figure 19 A, B). In addition, 
some immunoperoxidase reaction product was found to diffuse into the presynaptic 
compartment,  resulting  in  the  labeling  of  synaptic  vesicles.  An  identical  labeling 
pattern  was  observed in  hippocampal sections  prepared from  mGluR7a KI  mice 
(Figure 19 C, D). Thus, the synaptic distribution of mGluR7a was not altered by 
disruption of the mGluR7a-PICK1 interaction. 
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Figure  19.  Immunoelectron  microscopy  reveals  similar  presynaptic  localization  of 
mGluR7a in wild-type and KI mice. A-B. mGluR7a staining signal is mainly found at the 
presynaptic  membrane  in  the  CA-3  hippocampus  region  of  wild-type  mice.    In  addition, 
some labeling of synaptic vesicles was seen, probably due to reaction product diffusion. C-
D. Presynaptic localization of mGluR7a was not altered in KI mice. Scale bar, 0.1 µm 
 
3.2.6.  Loss  of  mGluR7a  mediated  presynaptic  inhibition  in  homozygous  KI 
mice 
 
Both the immunocytochemistry and the immunoelectron microscopy results indicate 
that the membrane trafficking and synaptic targeting of mGluR7a are not impaired 
in KI mice. To test whether mGluR7a mediated G-protein signaling and synaptic 
transmission are changed in KI mice, electrophysiological methods were used. It is 
well documented that activation of mGluR7 depresses synaptic transmission at a 
variety of central synapses (O'Connor et al., 1999; Perroy et al., 2002; Losonczy et 
al.,  2003).  This  aspect  of  mGluR7  function  was  tested  here  by  using  cerebellar   75 
granule  cell  culture  as  a  model  system.  It  has  to  be  mentioned  that  these 
experiments  were  performed  by  Dr.  Laurent  Fagni  from  Institute  of  Functional 
Genomics, CNRS UMR5203, Montpellier France. 
In  brief,  cerebellar  granule  cells  were  prepared  from  7  day-old  wild-type  and  KI 
mice. The cells were allowed to differentiate for 9-10 DIV. Spontaneous excitatory 
postsynaptic currents (sEPSCs) were then recorded at a membrane potential of -60 
mV in the absence and presence of L-AP4 (Figure 20A).  L-AP4 (400 µM)  was 
applied for 7-10 min. Quantification of the recorded events demonstrated that L-
AP4 dramatically reduced the frequency, but not the amplitude of EPSCs in wild-
type neurons. However, this inhibitory effect of L-AP4 on the recorded EPSCs was 
not observed in knock-in neurons (Figure 20B), indicating that the mGluR7a (AAA) 
did not respond properly to agonist stimulation. Therefore, it seems that mGluR7 
mediated presynaptic inhibition requires an interaction with PICK1. Taken together, 
these results corroborate the previous conclusion (Perroy et al., 2002) that PICK1 
has an essential role in mGluR7a G-protein dependent signaling, although it is not 
required for the synaptic targeting and localization of the receptor. 
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Figure 20. mGluR7 stimulation inhibits spontaneous EPSCs in wild-type but not KI 
cerebellar neurons. A. Recording of spontaneous EPSCs from both wild-type and knock-in 
cerebellar granule cells in the absence (CT, upper trace) and presence (lower trace) of L-
AP4. B. L-AP4 treatment decreased the frequency, but not the amplitude of the recorded 
EPSCs in wild-type neurons, whereas inhibitory effects of L-AP4 were absent in KI neurons. 
 
3.2.7. Increased susceptibility of the mGluR7 KI mice to convulsant drugs 
 
 
It has been reported that mGluR7 knock-out mice showed the increase in threshold 
sensitivity for the convulsant pentetrazole (PTZ) (Sansig et al., 2001a). We wondered 
whether the disruption of the mGluR7-PICK1 protein complexes and the associated 
signalling got involved in this hypersensitivity to convulsant drugs. In order to test 
that, we collaborated with Drs. Federica Bertaso, Joël Bockaert, and Mireille Lerner-
Natoli from Institute of Functional Genomics, CNRS UMR5203, Montpellier France. 
They performed the experiments using mGluR7a 
 KI mice aged 9 weeks or more.  
All analysis of the data were based on the detailed description made by Weiergraber 
et  al.  on  the  different  phases  of  the  symptoms  developed  by  mice  injected  with 
pentetrazole  (Weiergraber  et  al.,  2006).  According  to  their  grading,  phase  1 
corresponds  to  an  "absence-like,  non-convulsive  state,  with  reduced  motility  and   77 
typical prostrated position of the animal; phase 2 shows partial clonus of the head, 
vibrissae  and/or  forelimbs;  phase  3  implies  a  generalized  myoclonus  of  the  four 
members and the tail and vocalisation; this phase can develop into typical "running 
fits"; phase 4 corresponds to a generalized tonic-clonic seizure with tonic extension 
of the four limbs; this phase is eventually followed by death of the animal, due to 
respiratory insufficiency. Examples of electroencephalogram (EEG) traces recorded 
in wild-type mice administered with 70 mg/kg PTZ are shown in Figure 21A. Different 
doses of pentetrazole were tested on n = 6 or 7 mice per genotype and per dose and 
the results are summarized in Figure 21C. At the lowest dose of PTZ (40 mg/kg) all 
the  wild-type  animals  entered  phase  1,  with  typical  prostration  and  spindles 
appearing on the  EEG recording.  At the same  dose, four  KI mice showed partial 
myoclonus typical of phase 2, whereas two animals died as consequence of a rapidly 
developing  tonic-clonic  seizures.  At  50  mg/kg  PTZ  all  wild-type  animals  entered 
phase 2, whereas all the KI mice showed at least a generalized myoclonus (phase 
3), while 4 animals died of phase 4 seizures. We tested higher doses only on wild-
type  animals,  to  ensure  that  they  were  indeed  able  to  develop  clonic  seizures. 
Overall, wild-type mice showed a greater resistance to PTZ than KI mice, with 80 
mg/kg being necessary for all the animals to develop either phase 3 or 4 seizures. 
Moreover and opposite to the KI  mice,  all the  animals survived the  phase  4  and 
recovered within 30 minutes.   78 
 
 
Figure 21. Increased susceptibility of mGluR7 KI mice to convulsant drugs. A. Example 
EEG  recordings  from  wild-type  mice  injected  with  70  mg/kg  in  the  different  PTZ-induced 
epileptic phases. B.  Example  EEG recordings  from  wild-type and KI  mice treated with 50 
mg/kg PTZ. Note KI mice have the greater sensitivity to PTZ. C. Percentage of animals in the 
different  phases  (see  colour-coded  legend)  after  intraperitoneal  administration  of  the 
indicated doses of PTZ. 
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3.2.8. mGluR7a KI mice develop spontaneous absence-like seizures 
 
 After  establishing  that  mGluR7a  KI  mice  displayed  hypersensitivity  to  convulsant 
drugs, we went further to check whether the KI mice develop any form of epilepsy 
phynotype.  Dr.  Federica  Bertaso  performed  the  surface  electroencephalogram 
(EEG) recordings of the KI mice. Indeed, the mGluR7
 KI mice showed spontaneous 
seizures  that  displayed  similar  characteristics  to  absence-like  spike-and-wave 
discharges (SWD) (Figure 22A). These mice showed on average 28 ± 5 seizures 
over a 20 min observation period, each seizure having with a mean frequency of 7.7 
± 0.6 Hz and mean duration of 1.43 ± 0.04 s (Figure 22B, C). Notably, the KI mice 
displayed  the  behavioural  arrest,  associated  to  facial  myoclonus  and  vibrissal 
twitching during the SWD. As the absence-like seizures should respond to anti- and 
pro-absence specific drugs (Manning et al., 2003), we tested commonly used anti-
absence  drug,  ethosuximide,  which  reduces  the  severity  of  the  seizures  and 
Carbamazepine  (CBZ)  which  is  able  to  worsen  absence  epilepsy.  The  results 
showed  that  the  seizures  of  KI  mice  have  the  same  pharmacological  profile  as 
absence epilepsy described in human being and mouse (Figure 22 B, C). And also, 
the EEG recording demonstrated that the absence-like seizures appeared once the 
mice were adapted to a quiet and silent experimental environment. However, it is 
necessary to point out that no any other spontaneous epileptic events were observed 
for the KI mice, the absence seizures we found here are only visible on the EEG 
recording, therefore are well far from the classical myoclonic or tonico-clonic epileptic 
seizures.  Nevertheless,  these  data  indicated  that  alteration  of  the  mGluR7a  PDZ 
ligand motif is sufficient to develop absence-like seizures in the mouse.  
The above experiments were carried out on mGluR7a KI mice aged more than 8 
weeks. We also analysed the phenotype of younger KI animals and found that the 
spontaneous seizures were absent in mice younger than 5 weeks and present in the 
totality of the animals tested aged 9 weeks or more (Figure22 D).    80 
 
 
Figure 22. Absence –like seizures of mGluR7a KI mice. A. Comparison of cortical EEG 
recordings  obtained  from  one  wild-type  mouse  (top  traces)  and  one  mGluR7a  KI  mouse 
(bottom traces). B-C. Histograms of number of seizures and mean seizure duration over a 20 
min period after drug treatment (* p< 0.05, ** p<0.01, student’s t test compared to control). D. 
Age-related development of the absence-like phenotype in KI mice. The plot represent the 
percentage of animals showing seizures for the total number of animals tested (n = 6 to 7 per 
age). 
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3.3. Behavioral analysis of mGluR7a KI mice 
 
A variety of behavioral test strategies have been developed and extensively used 
for  characterizing  phenotypic  changes  of  many  different  mutant  mouse  lines. 
Behavioral phenotyping is of prime importance for the analysis of targeted gene 
mutations.  Here,  different  numerous  commonly  used  mouse  behavior  test 
paradigms were used for studying the mGluR7a KI mice. The aim was to find out 
whether  this  mouse  line  has  deficits  in  locomotion  and  emotional  activity,  pain 
sensitivity, startle response and spatial learning. 
All animal experiments discussed below were subjected to institutional review and 
conducted in accordance with the veterinary authority of Germany. Age-matched 
(2-3  months  old)  and  gender-matched  (only  male  mice)  mutant  and  wild-type 
littermates were used for all tests described below. Mice were housed individually 
in cages  in temperature-regulated rooms  with  a 12-h light :  12-h  dark cycle.  All 
behavioral experiments were conducted during the light phase of the diurnal cycle. 
 
3.3.1. Open field  
 
The  open  field  test  is  a  relatively  simple  assay  which  is  designed  to  measure 
several  behavioral  responses  such  as  locomotor  activity,  hyperactivity  and 
exploratory behavior. The open field test is also used as an assessment of anxiety-
related traits (Dishman et al., 1988; Markel et al., 1989).  Generally, mice tend to 
avoid brightly illuminated, novel and open spaces; so the open field environment 
acts as an anxiogenic stimulus and therefore can be used for the measurement of 
anxiety-induced changes in locomotor activity and exploratory behavior.  
mGluR7a KI mice and wild-type littermates were subjected to the open field test at 
the same condition. Table 3 shows the summarized results of this test. All values 
are expressed as means + SEM. In the open field and exploration tasks, mGluR7a 
knock-in mice showed a tendency to cover less distance during the test. On the 
other hand, they spent slightly more time and traveled somewhat more distance in 
the center, suggesting that these mice maybe less anxious than wild-type animals.   82 
However,  these  differences  were  not  statistically  significant.  The  anxiety–related 
traits were further studied using the elevated plus maze. 
 
Table 3.  Summary of open field test resultd for wild-type and mGluR7a KI mice 
 
 
 
mGluR7a
+/+                     mGluR7a 
AAA/AAA 
(n=8)                                   (n=8) 
Total distance traveled (cm)  2019 + 333                     1605 + 280   
Visits in center  19 + 5                              17 + 2 
% distance traveled in center  18 + 3                              20 + 3 
% time spent in center  12 + 3                              15 + 3 
 
3.3.2. Tail flick test 
 
The tail flick test is a pain assay in which a mouse’s tail is exposed to a heating 
device and the latency of the mouse to remove its tail from the heat is recorded. 
This latency is used as a measure to indicate neurological pain sensitivity (Harris et 
al., 1988; Hentall and Fields, 1988). mGluR7a KI mice and wild-type controls were 
subjected  to  this  test,  and  no  difference  was  observed  between  the  genotypes 
(Figure 23). It seems that disturbance of the mGluR7a-PICK1 interaction does not 
interfere with the signaling pathways required for pain sensation. 
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Figure  23.  Tail  flick  test  with  mGluR7a  KI  mice  and  wild-type  littermates.  Tail  flick 
latencies of mGluR7a knock-in mice did not differ from wild-type controls (n=8 each). Bars 
represent mean values + SEM. 
 
 
3.3.3. Acoustic startle response and prepulse inhibition 
 
The  acoustic  startle  response  (ASR)  is  a  transient  motor  response  to  an 
unexpected stimulus. The response is determined by stimulus parameters such as 
intensity, rise time and duration. The acoustic startle reflex has been observed in 
many species (e.g. rats, mice and also humans). In rodents, the startle response is 
characterized  by  contractions  of  the  major  body  muscles.  General  information 
about sensory-motor processing can be achieved from acoustic startle response 
experiments (Seaman et al., 1994; Storozeva and Pletnicov, 1994). As for prepulse 
inhibition  (PPI), it  is often  used to  measure sensorimotor  gating in  humans and 
animals (Arguello and Gogos, 2006). In response to a stimulus (pulse), the animal 
exhibits a quantifiable, reflexive startle response. If, however, a brief, low-intensity 
acoustic  prepulse  precedes  the  loud  noise  (pulse),  the  startle  response  is 
diminished.  The  magnitude  of change is then  expressed  as percent PPI. PPI is   84 
believed to reflect the ability to screen out (filter or gate) irrelevant environmental 
information. Studies have shown certain areas in the brain - the limbic system and 
the basal ganglia - are implicated in PPI.  
The startle response experiments were performed for both mGluR7a KI and wild-
type control mice. It was observed that KI and wild-type animals exhibited a stable 
response to the stimulus. A slightly, but not significantly, different startle amplitude, 
was observed  between  wild-type and  mutants (Figure  24, A).  mGluR7a  Ki  mice 
showed  a  somewhat  higher  startle  amplitude  than  the  control  mice.  Different 
studies have implicated PICK1 as a susceptibility gene for schizophrenia (Hong et 
al.,  2004;  Fujii  et  al.,  2006).  Hence,  there  could  be  an  association  between 
mGluR7a-PICK1  pathway  and  schizophrenia.  PPI  is  extensively  used  to  study 
oversensitivity  to  stimuli  in  schizophrenic  patients.  Therefore,  the  PPI  was  also 
measured  for  mGluR7a  KI  and  wild-type  control  mice.  This  revealed  that  no 
obvious  defect  in  PPI  for  the  mGluR7a  KI  mice  (Figure  24,  B).  However,  when 
increasing the intensity of the prepulse stimulus, the results of wild-type and mutant 
mice  started  to  diverge;  however,  never  a  significant  difference  was  reached 
(Figure 24, B). Taken together, the mGluR7a-PICK1 signaling pathways seem not 
to be significantly correlated with startle response and prepulse inhibition. 
 
                
Figure  24.  Startle  response  and  PPI  in  wild-type  and  mGluR7a  KI  mice  (n=12  per 
genotype). A. The indicated startle amplitudes were measured at the intensity of 100 dB. 
B. The PPI is measured as percent startle response to a 100-dB pulse for prepulses of the 
indicated intensities. Values are expressed as means + SEM.   85 
3.3.4. Elevated plus-maze 
The elevated plus-maze is widely used as an anxiety measurement and is based 
on  unconditioned  responses  of  mice  to  a  potentially  dangerous  environment.  A 
combination of maze height, luminosity and open space is assumed to induce fear 
or anxiety. The animal’s anxious behavior is assessed by measuring the time spent 
in  the  open  and  closed  arms.  When  placing  mGluR7a  KI  mice  and  wild-type 
littermates in the elevated plus-maze, the performance of the animals revealed that 
the  mutant  mice  were  more  active  in  exploring  the  maze  than  wild-type  mice. 
Accordingly, a higher number of open arm entries were observed for the mutant 
mice. Notably, mGluR7a KI mice spent more time in the open arms than wild-type 
littermates  (Figure  25A,  B),  suggesting  that  the  mutation  somehow  is  anxiolytic. 
Based  on  these  observations,  the  mGluR7a-PICK1  interaction  appears  to  be 
relevant in signaling pathways of fear and anxiety. 
 
 
Figure 25. Elevated plus maze performance of mGluR7a KI and wild-type mice (n=12 
per  genotype).  A.  mGluR7a  KI  mice  showed  anxiolysis  in  this  test,  as  indicated  by 
spending more time in the open arms (P=0.22, student’s t test). B. An increased ratio of 
open/closed  arm  as  compared  to  wild-type  mice  (P=0.17,  student’s  t  test).  Data  are 
presented as means + SEM. 
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3.3.5. Barnes maze 
 
The Barnes Maze is designed to disclose capacity of spatial learning and memory 
in rats and mice (Barnes, 1979; Bach et al., 1995). Upon exposure to the Barnes 
Maze, animals intend to  escape from the brightly lit, open  platform surface to a 
tunnel that is connected to a target box underneath the holes of the maze. During 
testing, the animal learns the spatial location of the particular hole which allows to 
escape from the surface of the maze to the target box. In general, the Barnes Maze 
is used to  monitor the hippocampus-dependent long-term spatial  memory of the 
animal. 
When  mice learn to perform  in the Barnes  maze, they use  a fixed sequence of 
three search strategies: random, serial, and spatial.  The strategies can be simply 
recognized, analyzed, and quantified. By seeing which strategies the animals use, 
one  can  determine  whether  an  animal  learns  the  task  and  thereby  judge  the 
animal’s spatial memory capability. 
Here, the mGluR7a KI mice and wild type littermates were tested on the spatial 
version of the Barnes circular  maze.  The results indicated that the  mutant  mice 
learned  random,  serial,  and  spatial  search  strategies  as  well  as  control  mice 
(Figure  26,  A,  B,  C).  Both  wild-type  and  mutant  animals  initially  employed  the 
random search strategy, spending more than half of the time using this strategy 
during the first 5 sessions. Upon further training, the mutant mice learned the serial, 
and spatial search strategies with similar speed as control mice. Finally, almost the 
same  number  of  the  mice  acquired  the  task  within  the  32  sessions  of  the  test 
(Figure 26, D). Therefore, we conclude that the mGluR7a KI mice are not defective 
in  spatial  learning.  Apparently,  the  mGluR7a-PICK1  signaling  pathways  are  not 
important for long-tem learning and memory.   87 
 
Figure  26.  In  the  Barnes  maze  test,  mGluR7a  KI  mice  show  a  spatial  learning 
performance similar to that of wild-type mice 
Both mutant and wild-type mice employed random (A), serial (B) and spatial (C) search 
strategies. No learning deficiency was found for the KI mice. D. Percentage of mutant and 
wild-type mice acquired the task of the Barnes maze. 
 
 
4. Discussion 
 
In  this  thesis,  the  functional  role  of  PICK1  in  mGluR7  signaling  and  synaptic 
targeting was investigated by generating a knock-in mouse in which the mGluR7a-
PICK1 interaction was disrupted. For gene targeting, mouse genomic DNA isolated 
from  a  BAC  clone  was  used  for  the  construction  of  a  targeting  vector  which 
contained exon 10 of the mGluR7 gene. The bases encoding the three C-terminal 
amino  acids  of  mGluR7a  (-LVI)  were  mutated  by  site-directed  mutagenesis  to 
generate alanine codons (resulting tail sequence -AAA). The targeting vector was 
then  introduced  into  mouse  129/OLA  embryonic  stem  cells.  Homologous   88 
recombination events were confirmed by Southern blot analysis. Removal of the 
loxP-flanked  neomycin  cassette  was  achieved  by  transfection  with  the  Cre-
recombinase  expression  plasmid,  and  properly  targeted  clones  were  used  for 
blastocyst  injection  to  generate  chimeric  mice.  Chimeras  were  backcrossed  to 
C57BL6  mice,  and  the  resulting  heterozygous  offspring  was  bred  further  to 
generate wild-type, heterozygous and homozygous mGluR7a knock-in mice. The 
presence of the mutation was confirmed by DNA sequencing, and then the mutant 
mice served as a model for studying the role of protein interaction at the mGluR7 
C-terminus in glutamatergic signal transduction mechanisms. 
 
4.1. Knock-in approach and the role of  proteins interacting with  C-terminal 
region of mGluR7 
 
In this work, the PICK1 interaction site was mutated in the tail region of mGluR7a. 
Detailed analysis of the generated mouse line showed that the expression level of 
mGluR7a protein was reduced by 40%, which suggests interaction with proteins, 
like PICK1 might stabilize mGluR7a at the presynaptic membrane. The removal of 
PICK1 binding might enhance internalization of mGluR7a. Future investigations of 
this aspect might provide insights into the membrane recycling of mGluR7a. On the 
other hand, the triple alanine mutation introduced into the mGluR7a gene did not 
alter  the  brain  anatomy  and  mGluR7a  distribution.  Co-immunoprecipitation 
confirmed the loss of mGluR7a-PICK1 interaction, this mutant mouse line therefore 
constitutes a reliable model for investigating mGluR-PDZ protein interaction in vivo. 
Based  on  the  analysis  of  mGluR7a  knock-in  mice  described  here,  it  becomes 
obvious that the same approach could be used to analyze the functions of other 
proteins interacting with C-terminal end of mGluR7. Proteins shown to interact with 
the C-terminus of mGluR7 can be classified into actin binding (Filamin-A, Tubulin), 
scaffolding  (GRIP,  PICK1)  and  signaling  (syntenin,  protein  phosphaase  1,  Gβγ 
subunits,  calmodulin)  proteins  (O'Connor  et  al.,  1999;  El  Far  et  al.,  2000;  Enz, 
2002;  Hirbec et al., 2002).  So far,  no clear function has  been  demonstrated for 
other mGluR7 interacting proteins. In fact, the generation of knock-in mice in which 
respective  protein  interactions are  inactivated provides a very  useful  method for   89 
studying  their  physiological  roles,  because  the  phenotype  of  the  mice  can  be 
analyzed  at  many  different  levels.  With  additional  functional  studies  on  mGluR7 
interacting  proteins,  the  membrane  trafficking  of  mGluR7  and  the  signaling 
cascades activated by this receptor  will  be  understood  more clearly. Respective 
progress should also create more options for testing new therapeutic targets, since 
protein interactions at mGluR7 are highly promising for drug discovery (Enz, 2007). 
 
4.2.  The  role  of  PICK1  in  the  presynaptic  targeting  and  localization  of 
mGluR7a 
 
PICK1  was  first  identified  as  binding  partner  for  protein  kinase  α  (PKCα) 
(Staudinger  et  al.,  1995)  and  was  therefore  termed  Protein  Interacting  with  C-
Kinase  1  (PICK1).  PICK1  comprises  a  single  PDZ  domain  which  mediates  the 
association  with other proteins. In addition, it also contains  other protein-protein 
interaction motifs, for instance, two coiled-coil motifs, which are involved in PICK1 
dimerization. Recently, a new Bin–Amphiphysin–Rvs (BAR) domain was identified 
in PICK1 (Jin et al., 2006). However, little is known about the function of this BAR 
domain. At the C-terminal of PICK1, a glutamate-/aspartate-rich (E/D) acidic region 
(E/D motif) has been suggested to regulate PICK1-mediated synaptic localization 
and  co-clustering  of  its  interacting  proteins.  Besides  mGluR7,  PICK1  has  been 
reported to interact with various membrane proteins, such as AMPA receptors (Xia 
et  al.,  1999),  dopamine  transporter  (DAT)  (Torres  et  al.,  2001),  and  the  ErbB 
receptors (Harrison and Owen, 2003). 
As a single PDZ-domain containing protein, PICK1 is generally believed to act as a 
scaffolding  protein,  which  is  located  at  neuronal  synapses  and  associates  with 
many different proteins via its functional domains (Dev, 2004). Notably, PICK1 co-
work  with  protein  kinase  C  (PKC)  and  regulates  the  phosphorylation  of  many 
PICK1  interaction  partners,  thereby  altering  their  synaptic  clustering,  and 
membrane recycling. The best-understood example of PICK1 function concerns its 
interaction with the AMPA receptors. Extensive work has shown that there is direct 
interaction between GluR2 subunit of AMPA receptors. It has been suggested that 
this interaction of GluR2 with PICK1 would allow to form an extrasynaptic pool of   90 
calcium-impermeable  AMPA  receptors  at  both  intracellular  and  extrasynaptic 
plasma membranes sites, which could be recruited to synapses upon stimulation 
(Gardner  et  al.,  2005).  Moreover,  it  was  reported  that  treatments  that  block 
interactions between the carboxy-terminal PDZ binding motif of GluR2/3 and PICK1 
strongly attenuate the expression of cerebellar LTD in cultured Purkinje cells (Xia et 
al., 2000). In case of another important PICK1 interacting partner, the DAT, Torres 
et  al.  (2001)  found  that  PICK1  binding  was  important  for  proper  targeting  and 
surface  clustering  of  the  transporter  protein,  since  overexpression  of  PICK1 
together with the DAT in HEK293 cells resulted in enhanced surface expression 
and  the  formation  of  cluster-like  structures;  Furthermore,  disruption  of  the  PDZ 
binding  site  in  DAT  impaired  transporter  distribution  in  neurons  (Torres  et  al., 
2001). 
Based on the roles of PICK1 at AMPA receptors and the DAT, one might expect 
that PICK1 may has a similar role in the regulation of mGluR7a surface clustering 
and  signaling  mechanism.  Actually,  two  groups  have  probed  the  functional 
consequences  of  PICK1-mGluR7a  interaction.  Dev  et  al.  (2000)  reported  that 
PICK1  may  play  a  role  for  modulating  PKCα  dependent  phosphorylation  of 
mGluR7a, thereby influencing the  mGluR7a signaling (Dev  et al.,  2000). Others 
(Boudin et al., 2000)  overexpressed wild-type mGluR7a and a mutant mGluR7a, 
which  lacked  the  PICK1  binding  site,  in  cultured  hippocampal  neurons.  They 
showed that wild-type mGluR7a receptor clusters were localized at synaptic sites 
and the receptors were targeted to axonal terminals. They could also show that the 
mutant mGluR7a, which does not bind to PICK1, was efficiently targeted to axons. 
However, contrasting with the wild-type mGluR7a, the mutant mGluR7a receptor 
immunoreactivity  was  not  concentrated  at  synaptic  sites,  but  exhibited  rather  a 
more  diffuse  pattern,  distributed  in  large  stretches  along  axonal  processes. 
Moreover,  double  localization  with  the  synaptic  marker  SV2  showed  no 
correspondence  between  mutant  mGluR7a-expressing  axonal  portions  and  the 
presence of synapses. They therefore concluded that the deletion of PICK1 binding 
domain  prevented  the  synaptic  aggregation  of  mGluR7a,  but  not  its  axonal 
targeting. 
The data obtained here with mGluR7a knock-in mice generated in this thesis are 
not  consistent  with  the  results  of  Boudin  et  al.  (2000).  Both  our   91 
immunocytochemical  data  obtained  with  hippocampal  neuron  cultures  and  the 
immunoelectron microscopy results with mouse brain tissue clearly show that there 
was no impairment of mGluR7a synaptic membrane targeting and localization in 
the  knock-in  mice.  This  indicates  that  PCK1  is  not  crucial  for  the  clustering  of 
mGluR7a at presynaptic active zones in vivo. It seems that some other targeting 
and  clustering  mechanisms  must  exist  for  this  receptor.    The  C–terminus  of 
mGluR7a probably contains a dominant and sufficient signal for both axon targeting 
and  synaptic  clustering  of  mGluR7a  that  is  independent  of  PICK1  and/or  other 
PDZ-domain proteins. To sum up, the results obtained with knock-in mice here do 
not support the conclusions reached by Boudin et al. (2000). It should be pointed 
out, however, that the transfection experiments in the latter study were performed 
on  the  wild-type  background;  hence,  the  endogenous  mGluR7a  may  have 
competed  with  the  recombinant  mutant  mGluR7a  for  other  binding  protein.  This 
question could be addressed by performing respective transfection experiments on 
hippocampal neurons from mGluR7 knockout mice. 
 
4.3. Requirement of PICK1 in the mGluR7a receptor signaling and control of 
synaptic transmission  
 
mGluR7 is one of the most important mGluR subtypes and is primarily localized on 
presynaptic  terminals  (Kinoshita  et  al.,  1998)  where  it  is  thought  to  regulate 
neurotransmitter release. Many studies indicate that this receptor is a key player for 
modulating  both  glutamatergic  and  GABAergic  transmission  (Losonczy  et  al., 
2003).  It  is  well  established  that  mGluR7  activation  depresses  synaptic 
transmission at a variety of synapses in neuronal cultures (O'Connor et al., 1999; 
Perroy  et  al.,  2002).  mGluR7  mediated  presynaptic  inhibition  probably  involves 
different mechanism; however, increasing evidence suggests that presynaptic Ca
2+ 
channels are the primary target of mGluR7 (Perroy et al., 2000; Millan et al., 2002; 
Millan et al., 2003). Their inhibition mediates down regulation of neurotransmitter 
release.  
To address the contribution of PICK1 in mGluR7a mediated synaptic transmission, 
the knock-in mice were analyzed electrophysiologically using cerebellar granule cell   92 
cultures as model system. Spontaneous excitatory postsynaptic currents (EPSCs) 
were recorded with cerebellar neuron cultures in the absence and presence of L-
AP4.  We  found  that  L-AP4  dramatically  reduced  the  frequency,  but  not  the 
amplitude of EPSCs in wild-type neurons. However, this inhibitory effect of L-AP4 
was lost in knock-in neurons, indicating that the mutant mGluR7a, which does not 
bind  to  PICK1,  did  not  responde  properly  to  agonist  stimulation.  We  therefore 
concluded that mGluR7 mediated presynaptic inhibition requires an interaction with 
PICK1. Moreover, these data corroborate the previous notion (Perroy et al., 2002) 
that  PICK1  has  an  essential  role  for  inhibition  of  P/Q-type  Ca
2+  channels  and 
syanptic  transmission  by  mGluR7.  Taken  together,  the  data  collected  from  the 
knock-in mouse model strongly suggest that the PICK1-mGluR7a protein complex 
at the presynaptic terminal determins the signaling specificity of mGluR7a and the 
control of synaptic transmission by mGluR7a is PICK1 dependent.  
Considering that the mGluR7a receptor has a low affinity for glutamate (Saugstad 
et al., 1994), this receptor is thought to be activated only when the concentration of 
glutamate in the synaptic cleft is highly elevated. This implies that the mGluR7a–
PICK1 complex mediated signaling pathway will be operative only under enhanced 
presynaptic activity in cerebellar granule cells, Excessive glutamate release would 
activate this pathway, and thereby decrease glutamate release and reduce synaptic 
transmission. The data shown here corroborate that mGluR7a mediates inhibition 
of glutamate release. 
 
4.4. Involvement of mGluR7a-PICK1 signaling pathway in anxiety 
 
Anxiety disorders represent a range of conditions that include generalized anxiety, 
panic attacks, post-traumatic stress disorder, obsessive-compulsive syndrome and 
social  phobias  (Martin,  1998).  These  disorders  are  often  resistant  to  current 
therapeutic approaches such as anxiolytic drug treatment and cognitive behavior 
therapy.  Novel  treatment  strategies  are  required,  and  manipulations  of  the 
glutamatergic system through mGluRs are widely considered a promising targets 
(Swanson et al., 2005). Previous studies of mGluR7 knockout mice has established 
the  notion  that  mGluR7  is  involved  in  anxiety-related  behavior,  and  that  this   93 
receptor  could  be  exploited  for  the  psychopharmacological  and  behavioral 
treatment of anxiety disorders (Cryan et al., 2003; Callaerts-Vegh et al., 2006). 
In  mGluR7a  knock-in  mice,  the  electrophysiological  analysis  revealed  that  the 
signaling of mGluR7a was blocked, we therefore exmined whether there are some 
alterations in anxiety-related behavior for the KI mice. The elevated plus-maze, a 
widely  used  anxiety  test,  was  employed  to  assess  the  mGluR7a  knock-in  mice. 
Although not statistically significant, a difference was found for the behavior of KI 
and  control  animal  in  elevated  plus-maze  test.  The  knock-in  mice  showed 
anxiolytic-like behavior, which is similar to the anxiety-related phenotype observed 
in mGluR7 knockout mice (Callaerts-Vegh et al., 2006). This provides the evidence 
of the significance of mGluR7 in anxiety pathways and mGluR7a-PICK1 interaction 
could  be  involved  in  these  processes.  Further  investigation  of  mGluR7-PICK1 
signaling  will  help  to  understand  the  detailes  of  their  involvement  in  anxiety 
pathways. 
 
4.5. mGluR7a knock-in mice – an animal model for absence epilepsy? 
 
Epilepsy is a chronic neurological disorder characterized by seizures that are quite 
diverse,  ranging  from  only  electrographically  detectable  seizures  (Petit  Mal)  to 
massive generalized seizures of the entire body musculature (Grand Mal). Among 
genes  related  to  epilepsy,  mGluR7  is  of  special  interests  because  it  may  be 
involved  in  absence  epilepsy  (Alexander  and  Godwin,  2006).  Typical  absence 
seizures  are  characterized  behaviourally  by  a  loss  of  consciousness  of  abrupt 
onset  and  a  termination  process  that  is  associated  with  a  bilateral  synchronous 
SWD measuring about 3 Hz in the human EEG and 5 Hz in mouse EEG (Manning 
et al., 2003). 
The analysis of the mGluR7a knock-in mice has shown that the increase in threshold 
sensitivity  for  the  convulsant  pentetrazole  (PTZ)  was  observed  in  the  KI  mice. 
Moreover, surface parietal cortex EEG recordings of the KI mice revealed a series of 
synchronous oscillation, or "spike-and-wave discharges" (SWD), and mean while the 
mutant mice displayed the behavioural arrest, associated to facial myoclonus and 
vibrissal twitching during the SWD. Notably, the KI mice responded to pharmacology   94 
as human absence epilepsy. Based on this observation, we defined that the KI mice 
displayed the phenotype of absence-like seizures.  
The question remains of what could be the mechanism of mGluR7’s acting on the 
absence-like seizures? The classic view of the seizures pathology believes that a 
thalamocortical circuit, particularly the contribution of the ventrobasal thalamus (VB) 
and reticular thalamic  nucleus  (RTN), are involved in the propagation of  absence 
seizures. Aberrant corticothalamic rhythms are believed to be the substrate of SWD 
(Gloor and Fariello, 1988). Studies have shown that expression of mGluR7 in the 
structures  involved  in  absence  seizures  (RTN,  VB  and  somatosensory  cortex) 
(Bradley et al., 1998; Kinoshita et al., 1998; Dalezios et al., 2002). It is possible that 
mGluR7 could exert their action on a range of synapses at different levels in these 
regions.  mGluR7  inhibits  Ca
2+  channel  and,  as  a  consequence,  neurotransmitter 
release and synaptic transmission. Data of this thesis showed that the mGluR7 PDZ 
ligand-dependent inhibition of EPSCs was mediated by blockade of Ca
2+ channels. 
Similarly  the  receptor  inhibits  Ca
2+  entry  through  N-type  Ca
2+  channels  in  cortical 
synaptosomes.  The  dysfunction  of  mGluR7  in  the  KI  mice  might  account  for  the 
pathophysiology of the  absence–like seizures. However, it is difficult to clarify the 
role  of  PICK1  in  these  processes,  the  detailed  analysis  of  mGluR7a-PICK1 
interaction  in  both  glutamatergic  and  GABAergic  neurotransmission  is  therefore 
required. 
Overall, our results provide an original animal model of absence epilepsy, a single 
identified  protein-protein  interaction  is  directly  linked  to  this  neuropathology.  This 
model  might  identify  mGluR7-PICK1  interaction  as  a  novel  anti-absence  seizure 
target.  Orthosteric  or  allosteric  mGluR7  agonists  or  compounds  reinforcing  the 
mGluR7–PDZ interactions could be of particular interest.   
 
4.6. The interaction of PICK1 with mGluR7a and mGluR7b 
 
The  yeast  two-hybrid  screens  identified  PICK1  as  a  binding  partner  of  the  C-
terminus  for  both  mGluR7a  and  mGluR7b  (El  Far  et  al.,  2000;  Enz  and  Croci, 
2003).  mGluR7a  and b differ only at the  C-termini. The  C-terminal last 3 amino 
acids of mGluR7a are required to bind PICK1 via its PDZ domain, while mGluR7b 
interacts with PICK1 through different binding motifs (Enz and Croci, 2003). The   95 
gene targeting strategy described in this thesis has mutated the last 3 amino acids 
residules  of mGluR7a, suggesting that only the  PICK1-mGluR7a interaction  was 
disrupted in the knock-in mice. In principle, the PICK1-mGluR7b interaction should 
not be affected in the mutant mice. One remaining question is whether the PICK1 
binding of mGluR7b will compensate for mutation-induced effects in the knock-in 
mice. However, anatomical data have shown that mGluR7a is more abundant than 
mGluR7b  in the central nervous system of the adult rat and mouse (Kinoshita et 
al., 1998). Although the mGluR7b splice variant also has been reported to display 
PICK1 binding ability, a at least 20-fold reduced efficacy as compared to mGluR7a 
was found upon quantifying the binding data (El Far et al., 2000).  On the other 
hand, little is known about the physiological function of mGluR7b, its contribution to 
brain function seems less apparent than that of mGluR7a. The outlined reasons 
above  suggest  that  binding  of  PICK1  to  mGluR7b  should  not  have  biased  the 
analysis of the mGluR7a knock-in mice. The results on the role of PICK1 and/or 
other  PDZ-domain  proteins  in  mGluR7a  mediated  signaling  pathways  could  be 
confidently studied in the mutant mice. 
 
4.7. Perspectives  
 
Disruption  of  the  mGluR7a-PICK1  interaction  in  the  knock-in  mice  resulted  in 
normal  targeting  and  synaptic  clustering  of  mGluR7a,  while  mGluR7a  mediated 
presynaptic inhibition  was abolished, this confers that PICK1 is not essential for 
receptor  membrane  trafficking  and  presynaptic  localization,  but  required  for  the 
receptor-mediated inhibition of presynaptic Ca
2+ channels. Three major questions 
arise from this for future work. 
First,  since  PDZ  domain-containing  proteins  obviously  play  a  central  role  in 
signaling  complex  assembly,  it  will  be  interesting  to  learn  whether  mGluR7  still 
organizes  its  signolosomes  efficiently  at  presynaptic  sites  in  mutant  mice  after 
inactivation  of  PICK1  binding.  This  question  has  to  be  investigated  by  further 
biochemical  experiments.  New  knowledge  on  this  will  shed  light  on  how 
supramolecular signaling complexes of mGluRs are formed.   96 
Second, the analysis of knock-in mice suggested an important role of PICK1 in the 
control of glutamatergic synaptic transmission. However, previous work has shown 
that the C-terminus of mGluR7a directly interacts with Ca
2+-Calmodulin at a binding 
site that overlaps with that of G-protein βγ subunits (O'Connor et al., 1999), and 
accordingly these interactions  are  mutually exclusive. It has been proposed that 
action  potential-induced  Ca
2+  influx  into  synaptic  terminals  might  activate 
calmodulin,  which  in  turn  would  displace  G-protein  βγ  subunits  from  mGluR7 
receptors to  activate presynaptic  Ca2+ channels, thereby causing depression  of 
glutamatergic synaptic transmission (O'Connor et al., 1999). Notably, both mGluR7 
receptor-coupled calmodulin and PICK1-dependent inhibitory pathways might act 
on  the  same  presynaptic  Ca
2+  channels.  It  would  be  interesting  to  test  whether 
these  two  pathways  are  complementary  or  exclusive.  Moreover,  if  a  functional 
crosstalk between these two signaling cascades could be found, this would lead to 
better understanding of intrcellular signaling mechanism of mGluR7. 
Third,  the  neurobiological  studies  of  mGluR7  function  have  correlated  mGluR7-
driven intracellular signaling pathways to synaptic plasticity (Pelkey et al., 2005). 
The  contribution  of  mGluR7-PICK1  interaction  and  downstream  signaling  to 
mGluR7-dependent synaptic plasticity could also be investigated using the knock-in 
mice  generated  in  this  thesis.  A  major  focus  of  such  studies  could  be  whether 
transcription and translation are changed by disrupting mGluR7-PICK1 interaction 
in  the  mutant  mice.  More  investigations  could  provide  insights  into  the  question 
whether mGluR7 has a role in the long-term regulation of synaptic efficacy in the 
central nervous system. 
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6. Appendices 
 
APPENDIX I.   Plasmid Map of pEasyFlox, which is used as backbone for 
construction of the gene targeting vector. 
 
 
 
 
APPENDIX II. Sequence of 9.8 kb genomic clone subcloned from BAC RP23-
391F16, the exon 10 is highlighted. 
 
AGATCTTTTTTTTCTTCTCTGCTTTTGGTTTTTTACATTTTTTTTATAGTTTCTTCAATCTAGTTTGCAAT
TAGCAAAAGTTTTTTAAGGCAAAAATTTGCAGAGTTGGGAGTGAGACAGCTCAGGGGTAAAGGTGC
TTGCTGCCACTGTGAGCCTCTGAGTTCCATCCACACAGTGCGACACGTGGACCACCTCACTCTATCTG
TCCTCTGAGCTCCACAACTATGCCACCGCCAGGATCCCCCTCCTTCCACAAATCAGAGTAGTTAAAA
AGCAAATCCTGGAGAAAGTTATATTAAAATTAAATTAATATTAAAATTGGCCTCCTAAGTCAATGCC
AAATTGACAGTACATTTTGACAAAATGAGAATGAATTGGATGTCTAATATTTACTAATAAGAAAATG
TGTATTAATAATGTATTTTAGAAATCAATGTCCTTAAGACTTTTTCATTGAAAACTTCAGGTCTTTTA
AATACCTGAGTTTGAGAAAAATGTAATAGGAACAATACAATCTACTCTTGTTCTTTCTCGATGTAAA  108 
CAGATTATTCCGTTCTTAAAAGCACTCGCTGTTCTTGGAGAACGCCCAGCTTCAGCTCCTAGCACCTA
CATCATGTCGCACAGTCATCCATAACTCCTGTTTCAGGGCATCTGACACCCTCTTCTGAGCTCTGTAA
GCAACGGGAACCCATATGGTACATATTCATACATGTAGGCAAAACATGCACACACATGAAATACAT
ATTTTTAATTTCATTCGACACACATTCTTAAAATAAAATGAAAATACTCCAGCTTCTGAGGGAAAGA
AATTTCCAGCCTTTCAACATAAAAGGCATATCTCTTTAACAACCATTTTTTCTGGACAACTATTTTGA
GCTAGGCAATTCTCTTCTCTGGACCATAAACTACATTGCTATTCAAATAAATAGAATTATCAGCCCTG
TAGGCACTTCTTTTATTTACTCATAAGGCCAGGATGGTTTAAAAATAAACACTATAATACACTGGACT
TTACTGTGATAAAGGGCAGAAATTGCCGTTCGAGGGGCTGCATAAACTTCATTATAACCTTGCTGCA
ACGCTCCAAAGCAATTCTGCAAAGAAAGCAGATACTGAGGCTTATCCTTTGTAGAGAAGTTTGTAAC
CTAAAAATACATTTATATGTTTTATTCCCCAGCGAGAGACTGGGATAATTCTGACATCTGTGCTATCA
ACAGTCCTCAGGGTCTGAATTACTGTCCTCATTTTAAAGCCTCCACAAAATTCAGCCTTATGGTAGAG
GGCTGGGCTCATCTCATGTAAGTGATGGAGCACAACTAGAACCCAGGCAGGTGAGTCCCAGGCAGC
AGTTTCTTCCCATGATGGCTTGCGGGGGAAAAAAAGAGAGACTCATGGGTCATCTAGCATGTTTTCT
CAAATGCTGGTCCCTCTGTGTTCCATGTCCCTCCCAACTATAAAGGGGAATAAAAATTATGTGTCTCA
TTTTCTGAAAATACAAGAAGATAATGCCCACAAAGCTTCAGGGAGCCTTGCCGTGTTCTCCAAAACA
TAATTTTCTAATTTTCATTTGTTTCATTGTTTTCTTGTTGCTAACTTGGGGTTTCACCTAGACCAGGCT
GGCCTCAAGCTTGTTGTGAAACTGAAAATGAACTTGCCCCACCCCCACCCCCATGCTTCTGTCCTCAC
CTGCTATGTACTGGGATGAGAGGCATGTAACACCACGCCTTACTCACCCAGTGCTTGGGGTGGAGCT
CAGGGCTCTGTGCACACTAAGCAAGTACTCTCTCAACTGAGTTCTATTCCCATCCCCACTCTCCAAGT
TTGTCTTATTCATTCTATGTATATGTTTGTCTGTATGTTTAGCTGTGGTCCCGAGACACATGGGAGGA
AGTCACAGGATAACTCGTGGGAATCAGTTTACTCTTCCCACTACGTTCATTGCACTCAAGTCTTTACA
TGCAGAATTCTCCCGCTGCCCCAAGTATCTAATTGTTAAAAAGCATAGCTAGATTTTGATTCCAACTT
AATCCAAACCAGTCTTCACTACAGCATAGGAACAGGGTTTTTCTGAGCTACAATTCTTTTAGTAAAA
AAAAAAAATCTTTATTGACTGCTATTATATAGTAACCTATTTGAGGAAATTTAATTATTCCTTTTCCA
CTAGACAATTCTGCTTGCACAGAATTCGGCATTAATTAGCCACACCATGGAGGTGTCTGAGATATTT
ACGTCAGTTCAGGCTTCTGGGGTTTTTGTTTGTTTTCTTTCCCTTTGGTCTGGAGGGTAATTAGCTCCT
TGGCATTTGACAAGGGGTACTGTTTTTTTTTTCTTTCCATTTTTTATTAGGTATTTAGCTCATTTACATT
TCCAATGCTATACCAAAAGTCCCCCATACCCACCCACCCCCACTCCCCTACCCGCCCACTCCCCCTTT
TTGGCCCTGGCGTTCCCCTGTTCTGGGGCATATAAAGTTTGTGTGTCCAATGGGCCTCTCTTTCCAGT
GATGGCCGACTAGGCCATCTTTTGATACATATGCAGCTAGAGTCAAGAGCTCTGGGGTACTGGTTAG
TTCATAATGTTGATCCTGGCGGTTCCTCAGAAAATTGGACATAGTACTACCGGAGGATCCAGCAATA
CCTCTCTTGGGCATATATCCAGAAGATGCCCCAACTGGTAAGAAGGACACATGCTCCACTATGTTCA
TAGCAGCCTTATTTATAATAGCCAGAAGCTGGAAAGATGCCCCTCAACAGAGGAATGGATACAGAA
AATGTGGTACATCTACACAATGGAGTACTACTCAGCTATTAAGAAGAATGAATTTATGAAATTCCTA
GCCAAATGGATGGACCTGGAGGGCATCATCCTGAGTGAGGTAACACATTCACAAAGGAACTCACAC
AATATGTACTCACTGATAAGTGGATATTAGCCCAAAACCTAGGATACCCAAGATATAAGATACAATT
TCCTAAACACATGAAACTCAAGAAAAATGAAGACTGAAGTGTGGACACTATGCCCCTCCTTAGAAGT
GGGAACAAAACACCCTTGGAAGGAGTTACAGAGACAAAGTTTGGAGCTGAGATGAAAGGATGGACC
ATGTAGAGACTGCCTTATCCAGGGATCCACCCCATAATCAGCATCCAAACGCTGACACCATTGCATA
CACTAGCAAGATTTTATCGAAAGGACCCAGATGTAGCTGTCTCTTGTGAGACTATGCCGGGGCCTAG
CAAACACAGAAGTGGATGCCCACAGTCAGCTAATTGATAGATTACAGGGCTCCCAATGGAGGAGCT
AGAGAAAGTACCCAAGGAGCTAAAGGGATCGACAAGGGGTACTGTTACAATGACTCTGTCTGTGTC
AGCTGAGGTTGGCTGACTGTGACACTGTAAATAAGGTTTGGAGTCAGCATCTTTAGAAAGTTTCCCC
CCTGAAGAGCTGGGGAGGGAGCCTAACTGGCAGAGAGCTTGCTTAGCAAGCTCCACCTCCCGGGTT
CAATTCTCACCCTTGCATTAAAGGATGTGATGATATGTACCTGTAATCTCAGCACTTTGGAGGTGCAG
ACAAGTGGATCAGAAGTTCAAAGCCCTGCTTGGACATATAAAGGGTTTAGGGGCAGCCTAGAATAC
AAGATACCCTATCTTAAAAAAAAATCCTATAAAGAACGTTCTTTATCTTCCTTATACCCCAAAGAAG
AAAGATGCTGAAGGCAAAGACACTGGAAGAGCCAAAGGAATGTTCTTGGGGGCTTGGAGTCCTCTG
AGGCTTAGTCCATGTGTTCATCAAGCGCAATGCATCATGATTAAAGTTTCAGGAGACGCTCACTTTC
ATGCAATTCTAGTTTCTTTTAATTTTATCTACTGAACACAATACTCTGTAACAGAGATATAAGTCTTC
CATTCAGAAATGCCAGAGGGTATATCTGAATTTCTCCATAAAATGAGATTCAACTTTGTAGTCTGTGC
AGAATATGTGGGGAAAAATGATGTTTTTGTGTGTAAATAGAATGTAGCACATAGACTATCCAGAGGC
TAGTTATAAGTACTTAGCACACTAATGCAGTGGCTTGGGCCTCCAAATCCACACTAGTCCCTGCTTAA
GAGTTCTGGAACGATTCATTTTTACTTTGCTGTGCCCCATGAACATCTCTATTGAGAATCTAAAAAGA
ATAAAGAAGTAAGCCATTGTCAAGTACACATGACAAAGAGTCTATACCTAATAGAAATTGATGCAA
CATGACTAAAACCGAATTGAGTCAAGAACCCATAACTTCACAGACTCAGTGTCATACAGAACTGAG
AACAAGAACCTAGGGATACTATAATACCTTGAAGTGTGTTTCCATCTCAAGCACAGAGAAAGGGCC
GCCTTTTGGCTCAGTGTGTAGTCCTGTGCCTACCATGGGAGAACCAGTAGGTGAGTATTTACTGGAA
ACCTGACTAGAGGAAAGAGTCCCAGGACTCTGAATAAAACAAGTTGTTCTGCTTCTGAGGAAAACA
AAGGTCCAGTGTGATTGTTCAGACATCGGAAAGCTTCCAGGTGTGCTTTTAAGCTAAATGGAAATTA
CCAAGAAGATTGTGATGTACACGTTGCTGACGAGATTGGAAAGGGGACGTCTAGCCATTTGATATTA
GGAATGCTAACCTGTAGATGCACTCAGCCAGACAAAATAAATGAATTCCAATGACACAGGACATCC  109 
TCCTCCAGGCAGTAGGCATTCCTTTTGAAAACGTTCAGGAAATGGTCACAGGATAAACATCTCTGAT
AAAAACCAGATCACCTTTGCAGCTTAGGGCTGGTTAATAAGAAAGCATGGTGGTCAATAATAAATCT
GATGATCTTATTGACCCCAAATGGGTGAGGTTGGGGACATATCAAAGAAGTGAATGAAGGTGAGTG
TGTATCACTGGCACATCAATCTTAGATTGGAATAAGCCTATAGATAAACGCAAAAATGCCAAAGTGT
ATGTGTATTCCTCAATGATGTCTCATTGTGTCTTGACTTGGTCCTGGAAATCATCCACGCTCTATCTTT
GAAAACAGGGTCATTGCCACAATTGACTTTTCCCTCTCTTTCTCTTCAGGCCCTGCTGCAA 
                                                                                          P     A      A 
AAAAGAAGTATGTCAGTTATAATAACCTGGTTATCTAA 
K      K     K      Y      V      S      Y     N     N      L      V      I     STOP 
 
CCTGTTCCATCCCATGGAACCACAGAGGAGGAAGACCTTGAATTATTCTGTCACCCAGCCTGGCGTA
GGACTCTTTTGGTCCTGCCTGCTTCCTATCTCTGGAGGAGCTTCCCCACGCGGGAGAGCAATGGCAG
AGGATCCACACATCCTGAACAGCTGCTTTATGAGACACCTTTACTTTATCTTGGCTTAAGAAGTCATT
GGCATCAGCACTGCCATCTTGGCTGCAATTCTGGACTCCCTACAGCAAAGGGAGAGTTGAGATTCAA
GTCCCACCCGGCTCTTTTGGATGAACCGCTGAGAGCCTCAGGACTGTTTTTGGGGGGCTGACTTGTCT
TTCTACGTACGTACTTCCAGGCTGCAAGGTTTTGAAATTTTCTGTACAGTTTGTGAGGACATTTGCAC
TTTGCCACTCAATGTCGTACCTCGGTTCACTGTTTGTTTTTGAATGCCCTGTTTTCATAGAATCCTATC
CTCTCAGATGGTGGAATCTTTGGGGAAACTTTAAAGTAACTAATTTTTATTTAAAAAAAAAATCTCG
GCAGACATAAGAGAACACAACCCCCCATGCACATCTGTAAATGACTGTATGGTTATGATTATAGTAC
CACGAAAAATCATGTTATTTTTTTTTAAGACACACACAAAAAGATACTTAAAGACCAAAAACTGTGC
TGGGAAGATATGCCCCACCTATCTTTGGTACATGGTAGGTGTTGTGATGGAAATGGAAAGCATTGGT
TAAATGGAATAGAGGTCTTGATCTTTGGAATGCATGCCGGTAATGTATTTTACAGTACATGTTAATA
ATTTATGTTTAATATTTGTATTTGTGTTCTCTTTTGTTATTTTACTTAGGGTATATGGATATTTTGCAAT
AATTTTAATGATTCTTAAGCTATTTGAAGGAAAGAATATGGATTTCTCATGTCTTGAGGTTTTGTTCA
TGCCCCTATGACTGACCAATGTGATAAGGACTTTAAAAAAGAAGCATGTATGTTTTTTACTGTTTGTA
AGAAGTACTTTCGTTAATCTTGCTGCTTATGTGTCAATTTAGTGGAAAAGAAATCCCTTGCTGAAAAA
AAAAATCCCTTTCCATTCTCTTCCAGTTCTGTGGTATTGTCCAAGAATGTATCAATAAAATACTTTGG
TTAACTTTTTTATTTTCTGTAGTAAGTGCTTTAGTTGTTCTCCCCAGCCCACCCTACCTCCACTTGTTT
ACAGCTTATTTGAAACCCTGGGCTACAGAACACTAAGGACAGCTCAGGTCCTAAGCTTCCAATAACA
GTGCGTGTGAACTGCACAGCAAAACCTAGAGGCACTGGTGAGTTCTCCTAGAAAAGGGACAATGAC
AAAACCCAAGCGTTCTTTCCCATTATAACTGAAGTTCAATCCTTAAGAATTCTCAGATGCTAACTCAG
CAAGTTGTCTATCAAAAACAAATAACAAGAAAGATAAGACAAAGAAATATTTGCTTACAGAAACAG
TACTCTGCAAAAAAGAATCATTAAAAAGTTAAACATTTCTAGAAAACTGAACTGAAAGGATGTAGG
GCTCAGGAACAGACAACGGAGACAATGGGCTTGGTTCTGCATACACATGTGGCATTGAGGTTTGTAG
AACCAAGATTAAAATGCAGTACTCCATGGTCTGTAGAAACAAAACAAAATAAGACAAACAAATAAG
CAAAAAACTAGGAAACTACTCACAGCAACATACACTCCAGGAACATACTATCATCTCCTTATACAGG
GTAGCACTGGTCTTAGCACTCCAAGTGGGCCCCCAAGTCCAATATTTATTGAAATATCCCCTGGCTG
AACAAGGGGGGATAGCTCAGATGAAATTGCAACTGCCACACAAGCAAGAAGACCCAAGTTTGATCC
CAGAATCCATATTAATAAAAAGCAAGACTCAGTGTTGTGGACTTATAATTCCTGAAGTGGAGAGGTA
AAGCCTGGCAGATCCCTGGAACATTCTAGAAGGTGACCAAACCTATTAGGTGACTCCCACACCAGCA
GGAAACCCTGTGTCAGAAAAATAGGAACATCACTCATGTTGACTTCTGCCCCCCCCACACACACACA
CATACAAACAGAGATGACAGAGACAGACAGAGAAAAAGAGAAGAGAAAGACAGAGAAATACCCAC
ACATATTTACATAGAACAGATTGGGTTAACAGATAGATTGGATGATGATAGACAGATACATACATAC
ATACATACATACATACATACATACATACATACATCAATAGATGATAGATAGATAGATAGATAGATAG
ATAGATAGATAGATAGATAATTGATAGAGAGAGAGAGAGATGATAGATAATTGGTAAAGGGATAAA
TACATAGATACAAAGACACATAGATACATAGATAGCTACATAGACAGAGATAGATGGAACACAGAC
AAATGATAGATGATAGATAGATAGATAGATAGATAGATAGATAGATAGATAGATAGATAGACAGAC
AGACAGTAGACAGATACATAGATGTGCAATCAATATTCCTTTGTCAACAATGTTTCCACAGTGCCAG
GTAAAACCCTCATATTTTTCCTACTTTTGGTCTCTGTTGAGTTTTTCCTATAGTCCCTTGTGAACAATG
CTTTCACAGAGACTCCAAAACTCATTTTAGTATCAGACTGCAGAAAATAAATTGCTTTTCCCAATTTC
TTCTATCCCTTCAACATCCTCAAACTAATAGACCATGGAGAAATTCCAAATCAAAGAAGAAACACAT
TTAAATCATTGACATTTTTTTCTCAAGCTGTAGAGTCAAACCCTGTATAGAAACTGTCTGCCCTTCCT
GCTGACTTGTAATCAGGTTGGTTATATAAACATTCTCCATGTCGTTAGCTAGAAAATGATTTGGATAA
AATCTACCTCATTAGAAAGAAAGGATGAAGAGAGAAATTTGACAAATGACTACTCAGCATGGCAGC
TCTCAGGAGCATGGCTTTTGTGACGACTAGCACCAATATTAGTCATTATATACTTTTTTCTTTTCTTTT
TTTTTTAAATTAATCATTCCACTCATTTACATCTAAAATAATATCCCACTTCCCAGTTACCCAGTTGCC
CTTCCACAATCCCCCATCCCACATCTGCCCTTTATTCCCTCCTTTGCCTCTATGACAGTGCGTCCCCAT
CCACCCACCATCTCTAACCTACCAACCCTCTCCCAACCCACCCTTCTAGCATCCCCCTACACTGGGGC
ATCAAACCTTCTCGGGACCAAAAACCTCTCCTTCTGTTGATGTCTGGCAAGACCATCCTCTGCTACAT
ATTTATCTGGAGCCATGGATCCCTCCCTATATACTCCTTGGTTGGTGGTCTAGTCTGTGGGAACACTG  110 
GGTCAGCTGATATTGTTTTTCCTATGGGGTTGCAATCTCCCTCTGCTCGTCCTGTCCTTCTTCCAGCTC
CCCAACTGGGGTTCCTGAGCTCAGTATGAAGGTTAGTTCCAAGCATAGACATTTGCATTGGTCAGTT
GCTCACTGAACCTCCCAAGGAACAGCCACATCAGGTTCCTGTCAGCAAGCACCTCTTGGCAATGGCA
ACAGTGTCAGGGTTTAGAGTCTGTAGAAAGGATGGATCCCCAGGTGGGCCCCCGATGACTGTTCCTT
CAGTCTCTGCCCCATGTTTTGTCCCTGTTCTTAAAGCAAACTTAATCTTGCAGTATCGTCACCTCTAG
GTGGGGAAACAGTTTATAATATACTATGTGAATAGCTCAGAGTGTTTTGTGGCCCTATTGTAAAGTC
ACTTTCATTAAAAAATTATACAAAAGATTTTCTTTTTCATTTTTTCAGATGTTCAACCAAGAGTACTA
AGAAGCTGAAGTCATATGCATATGGTACTAAGACTAGGACAGGGCTCCTTCTGAAAACACCCTGTTC
TATGTATTCATCTTCACAGTACAACTGAGCTAATAGTGATCAGTAATGAGGATGAAGGGGACGATAT
AGAACTATAGGAAATTATGAAATATATTATGTAGTTTATATAGGCTATGCATGTTATATACATTGAA
ATGTACATTTATATACATTGCACGCTCCTCAAATCCACTTCTAACACCTTGCACCACGTGCACCTCTT
ACAAAGTATTTGGGATTAAAGATTGTCTATAGACATAGAGCAAATGCATCAGAAAATACTATTATCG
TCTGATCTCTAACTTGTATCTGGCGTATCCTCCTCAAGGTCCTTTGTATGCTGAATGCATGGCTCCAG
ATTAACACGGTTGGAAAGTGGTAGAAACTATGAGCAGTGAGACCTAGGAAGAAGTGATCAGATCAT
TAGGGGTGTTGCCTAGAACAGTTCCCCCTAATAGTCTTCATTCCTCTCCAGTATTTTGTTGATCATTAT
CATGTCTGGTCTTTGCTGATACTGTTTGAAAGGACAGTCTTTGACCAGTAGCCCAGGGAAGCAATTT
ACTTGTTTTGCTTTTTTCTTTCTATAACGTATGATGCTCATCTGACTTTATAGATTTCTTTTGCTGCTTT
TGTCTGCCCCTTTTCAGTATTCTGTTTAAGAAGGTCAGATACTTTTACCTTTGCTCCTAGTAATTTCCT
AACAGACTTGCTCAACAGGTAGCAGATTATCCTATAGATATTTGCCTATGTTTCAGAGAAAAAAAGG
AGTGGATAAATGAAGTGCAAAACTGAAGGAACATGGCTAGAGATCT 
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7. Zusammenfassung 
 
Die Aminosäure Glutamat ist nicht nur ein Schlüsselmolekül im Stoffwechsel jeder 
Zelle,  sondern  sie  fungiert  auch  als  primärer  exzitatorischer  Neurotransmitter  im 
zentralen  Nervensystem  von  Säugetieren.  Erregende  Nervensignale,  die  durch 
Glutamat  vermittelt  werden,  spielen  bei  vielen  Prozessen  im  Gehirn  eine  Rolle, 
einschließlich kognitiver Leistungen wie zum Beispiel Lernen und Gedächtnisbildung. 
Glutamat bindet nach Sekretion in den synaptischen Spalt an Glutamat-Rezeptoren, 
wodurch  eine  Reihe  von  Signalkaskaden  im  nachgeschalteten  Neuron  aktiviert 
werden.  Es  werden  zwei  Klassen  von  Glutamat-Rezeptoren  unterschieden: 
ionotrope  Glutamatrezeptoren,  zu  denen  die  nach  ihren  jeweiligen  Agonisten 
benannten  NMDA-,  AMPA-  und  Kainat-Rezeptoren  zählen,  und  metabotrope 
Glutamat-Rezeptoren  (mGluR).  Bei  letzteren  handelt  es  sich  um  G-Protein 
gekoppelte  Rezeptoren,  welche  über  GTP-bindende  Proteine  die  Aktivierung 
intrazellulärer Signalkaskaden vermitteln. Diesen Rezeptoren werden Aufgaben bei 
der Regulation verschiedener Formen neuronaler Plastizität zugeschrieben. Es sind 
gegenwärtig  acht  Subtypen  bekannt  (mGluR1-8),  die  anhand  von 
Sequenzhomologien  und  pharmakologischen  Eigenschaften  in  drei  Gruppen  (I-III) 
eingeteilt  werden.  Von  besonderem  Interesse  für  diese  Doktorarbeit  war  die 
Untersuchung des zur Gruppe III zählenden, präsynaptisch lokalisierten Rezeptors 
mGluR7a. Es handelt sich dabei um einen sogenannten Autorezeptor, welcher nach 
Aktivierung durch Glutamat zu einer Verringerung der Transmitterfreisetzung in der 
Präsynapse führt. Die molekularen Mechanismen dieser Form von präsynaptischer 
Inhibition sind erst teilweise verstanden. Es wurde bereits gezeigt, daß die Reduktion 
der  Transmitterausschüttung  mit  einer  Hemmung  spannungsabhängiger  Kalzium-
Kanäle in der Präsynapse einhergeht. Allerdings ist noch unklar, ob diese Effekte 
direkt  durch  G-Proteine  vermittelt  werden  oder  weitere  Signalmoleküle  involviert 
sind.  Zur Analyse der funktionellen  Regulation von  mGluRs der  Gruppe III wurde 
weltweit in verschiedenen Arbeitsgruppen gezielt nach Interaktionspartnern für die 
einzelnen  Rezeptoren  gesucht.  Es  konnten  einige  Proteine  identifiziert  werden, 
welche  mit  mGluR7a  interagieren,  wie  z.B.  die  G-Protein-Untereinheit  bg, 
Calmodulin, MacMARCKS, Filamin-A u.a. Im Rahmen der vorliegenden Doktorarbeit 
soll  die  Interaktion  des  PKC-bindenden  Proteins  PICK1  mit  dem  Rezeptor-C-
Terminus genauer untersucht werden.    112 
Das  Protein  PICK1  verfügt  über  eine  PDZ  Domäne,  welche  die  Assoziation  mit 
anderen Proteinen, auch die mit mGluR7a, mediiert. Weitere Motive sind zwei coiled-
coil Motive, welche für die Dimerisierung von PICK1 verantwortlich sind; eine azide 
Glutamat-Aspartat-reiche  Region  (E/D  Motiv),  die  möglicherweise  in  Interaktionen 
mit  weiteren  Proteinen  eine  Rolle  spielt,  welche  die  synaptische  Lokalisation  des 
Rezeptors regulieren; sowie eine BAR Domäne, die an Membranlipide binden kann.  
Vorangegangene  Untersuchungen  zur  Interaktion  von  PICK1  mit  mGluR7a  legten 
die  Vermutung  nahe,  dass  PICK1  entweder  eine  entscheidende  Rolle  bei  der 
gezielten  Anhäufung  von  mGluR7a  am  Ort  der  Transmitterausschüttung  spielt 
und/oder  regulierend  auf  die  PKC-vermittelte  Signaltransduktion  einwirkt.  Jedoch 
konnte  weder  die  eine  noch  für  die  andere  Hypothese  aufgrund  des  Fehlens 
geeigneter in vivo Modelle experimentell belegt werden. Vor diesem Hintergrund ist 
die  Generation  einer  geeigneten  Mausmutante,  in  welcher  die  Interaktion  der 
Rezeptor-C-Terminus  von  mGluR7a  mit  PICK1  gestört  ist,  das  vornehmliche  Ziel 
dieser Doktorarbeit. 
Es  wurde  eine  knock-in  Maus  generiert,  in  welcher  die  drei  C-terminalen 
Aminosäuren  LVI  des  Rezeptors  mGluR7a  zu  Alaninresten  mutiert  wurden. 
Vorausgehende  Studien  hatten  gezeigt,  dass  diese  Mutationen  ausreichend  sind, 
um  die  PICK1-Interaktion  mit  dem  Rezeptor  zu  verhindern.  Ein  entsprechendes 
Targeting-Konstrukt wurde in murine embryonale Stammzellen 129/OLA transfiziert 
und  homologe  Rekombinationsereignisse  mittels  Southern  Blot  analysiert.  Durch 
Transfektion  eines  Cre-Rekombinase  Expressionsvektors  wurde  die  gefloxte 
Neomycin-Kassette  entfernt  und  die  Mutation  tragenden  Klone  wurden  für  die 
Injektionen von Blastocysten verwendet. Chimäre Mäuse wurden in C57BL6 Mäuse 
zurückgekreuzt,  deren  heterozygote  Nachkommen  für  die  Züchtung  von 
homozygoten mGluR7a knock-in (mGluR7a
AAA/AAA) Mäusen verwendet wurden. Die 
initiale  Charakterisierung  der  knock-in  Mäuse  erfolgte  mittels  Northern  Blot.  Es 
konnte gezeigt werden, dass die mGluR7a mRNA sowohl in der Mutante als auch im 
Wildtyp etwa gleich stark exprimiert wird. Zum exakten Nachweis der Tripel-Alanin-
Mutation  des  Rezeptor-C-Terminus  in  knock-in-Tieren,  wurde  die  intrazelluläre 
Region  von  mGluR7a  mittels  RT-PCR  amplifiziert.  Die  Sequenzanalyse  des  RT-
PCR-Produktes  bewies,  dass  das  PICK-Bindungsmotiv  durch  drei  Alaninreste 
ersetzt worden war. Zusätzlich wurde auch die Höhe des mutierten Rezeptorproteins 
in  den  knock-in-Tieren  mit  dem  des  Wildtyprezeptors  in  Kontrolltieren  vermittels   113 
Western  blotting  verglichen.  Die  Quantifizierung  der  Ergebnisse  ergab,  dass  die 
Proteinexpression in heterozygoten Tieren in geringem Maße und in homozygoten 
Mäusen um 40% im Vergleich zu Wildtyptieren reduziert ist. Dieses Ergebnis lässt 
vermuten, dass PICK einen stabilisierenden Effekt auf mGluR7a ausübt, der, wenn 
die  Bindung  zwischen  den  beiden  Proteinen  unterbunden  wird,  fehlt  und  somit 
eventuell zur schnelleren Degradation des Rezeptors führt. 
Um  die  fehlende  Interaktion  der  Proteine  PICK1  und  mGluR7a
AAA/AAA  in  vivo 
nachzuweisen,  wurde  eine  Koimmunopräziptation  mit  einem  Antikörper,  der 
spezifisch  das  PICK-Protein  erkennt,  aus  Hirnhomogenaten  durchgeführt.  Hierbei 
ließ sich aus dem Lysat von Kontrolltieren neben PICK1 auch mGluR7a isolieren, 
während  aus  dem  Hirnlysat  von  knock-in-Tieren  nur  PICK1  präzipitiert  werden 
konnte. Zusammengefasst zeigt dies, dass  in  den  mutierten  Mäusen die Bindung 
zwischen  PICK1  und  mGluR7a  nicht  zustande  kommt.  Jedoch  scheint  die 
Verhinderung der Wechselwirkung der beiden Interaktionspartner keine Auswirkung 
auf  die  generelle  Lokalisation  des  Rezeptors  im  Gehirn  und  auf  die 
Gehirnmorphologie zu haben, wie histologische Färbungen des Gehirns von knock-
in-Mäusen zeigten. 
Da  PICK1  vermutlich  als  eine  Art  Adaptorprotein  fungiert,  welches  für  die 
Organisation  der  Präsynapse  ist,  wurde  die  Lokalisation  des  präsynaptisch 
lokalisierten  mGluR7a  Rezeptors  in  kultivierten  hippokampalen  Neuronen 
untersucht. Immunfärbungen ergaben sowohl für Nervenzellen aus Wildtyp- als auch 
aus knock-in-Mäusen die gleiche Verteilung des Rezeptor: in beiden Fällen konnten 
die für mGluR7a typischen punktförmigen Anhäufungen gezeigt werden, die mit dem 
präsynaptischen Markerprotein Synapsin kolokalisierten. Auch bei ultrastrukturellen 
Untersuchungen  der  subzellulären  Lokalisation  des  Rezeptors  in  hippokamaplen 
Synapsen  mittels  Immunoelektronenmikroskopie  fanden  sich  keine  Unterschiede 
zwischen  Wildtyp  und  mutierten  Mäusen:  in  der  CA3  Region  des  Hippokampus 
konnten  konzentrierte  Ansammlungen  von  mGluR7a  in  den  aktiven  Zonen  der 
präsynaptischen Endigungen nachgewiesen werden. Diese Ergebnisse wiederlegen 
also  die  Annahme,  dass  die  Interaktion  zwischen  PICK1  und  mGluR7a  ein 
entscheidender Faktor für den zielgerichteten Transport des Rezeptors zur Membran 
und dessen synaptische Lokalisation sein soll.  
Um die Effekte der eingefügten Mutation funktionell zu untersuchen, wurde vermittels 
elekrophysiologischer  Analysen  untersucht,  ob  die  synaptische  Transmission  in   114 
kultivierten zerebellären Körnerzellen von mGluR7a
AAA/AAA verändert ist. Es wurden 
spontane EPSCs bei einem Membranpotential von  
-60mV in An- und Abwesenheit des Agonisten L-AP4 gemessen. L-AP4 reduzierte 
die  Frequenz  der  EPSCs  in  Wildtyp-Neuronen,  jedoch  nicht  in    denen  von 
mGluR7a
AAA/AAA  Mäusen.  Somit  scheint  für  die  durch  mGluR7  vermittelte 
präsynaptische Inhibition die Interaktion mit PICK1 erforderlich zu sein.  
Schließlich  wurden  die  mutierten  Mäuse  auf  eine  Änderung  des  Phänotyps 
untersucht.  Verschiedene  Verhaltenstests  ergaben,  daß  Lokomotion,  emotionale 
Aktivität, Schmerzempfindlichkeit, Schreckreaktion und räumliches Lernen bei  den 
mutierten  Tieren  ungestört  ist.  Bei  Analyse  der  Ängstlichkeit  und  des 
Schreckreflexes  wiesen  die  knock-in-Tiere  eine  Tendenz  zu  einer  erhöhten 
Amplitude der Schreckreaktion auf, wobei jedoch kein statistisch signifikanter Wert 
erreicht  wurde. Zusätzlich  wurde die räumliche  Erinnerungsfähigkeit der  mutierten 
Mäuse  untersucht,  die  bei  mGluR7-defizienten  Tieren  verändert  ist,  wobei  die 
mGluR7a
AAA/AAA Mäuse jedoch keine Defizite zeigten.  
In weiteren Experimenten wurden die Vulnerabilität der knock-in Tiere für Pentetrazol 
(PTZ)-induzierte  epileptische  Anfälle  hin  untersucht.  Wildtyp-  und  knock-in  Mäuse 
wurden  im  Alter  von  9  Wochen  verschiedene  Mengen  PTZ  injiziert  und  die 
Gehirnströme  in  einem  Elektroenzephalogramm  über  mehrere  Stunden 
aufgezeichnet. Die knock-in Tiere zeigten eine größere Neigung zu PTZ-induzierten 
epileptischen  Anfällen.  Weiterhin  konnte  nachgewiesen  werden,  daß  die  knock-in 
Tiere  spontane  Anfälle  hatten,  welche  den  spike-and-wave  Entladungen  des 
Absence-Phänotyps  ähnelten.  Begleitet  waren  diese  Anfälle  von  motorischen 
Entäusserungen  wie  z.B.  Zuckungen  der  fazialen  Muskulatur.  Zusammenfassend 
weisen  diese  Experimente  darauf  hin,  daß  eine  Veränderung  der  mGluR7a-PDZ-
Interaktion ausreichend ist, um den Phänotyp einer spontanen oder pharmakologisch 
induzierten Absence- Epilepsie herbeizuführen. 
Zukünftig  könnte  die  knock-in  Mauslinie,  die  in  dieser  Arbeit  generiert  wurde,  als 
Modellsystem für pharmakologische Studien zur Absence-Epilepsie dienen. Ferner 
könnten  weitere  Interaktionspartner  von  mGluR7a  in  Analogie  zu  dem 
beschriebenen  Mausmodell  untersucht  werden.  Solche  weiterführenden 
Experimente könnten weitere Aufschlüsse über die Relevanz von mGluR7a bei der 
Regulation unterschiedlicher Funktionen im zentralen Nervensystem ergeben. 
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